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ABSTRACT

Metabolic reprogramming has been shown to be a major cancer hallmark
providing tumor cells with significant advantages for survival, proliferation,
growth, metastasis and resistance against anti-cancer therapies. Glycolysis,
glutaminolysis and mitochondrial biogenesis are among the most essential
cancer metabolic alterations because these pathways provide cancer cells with
not only energy but also crucial metabolites to support large-scale biosynthesis,
rapid proliferation and tumorigenesis. In this study, we find that 14-3-3σ
suppresses all these three metabolic processes by promoting the degradation of
their main driver, c-Myc. In fact, 14-3-3σ significantly enhances c-Myc polyubiquitination and subsequent degradation, reduces c-Myc transcriptional
activity, and down-regulates c-Myc-induced metabolic target genes expression.
Therefore, 14-3-3σ remarkably blocks glycolysis, decreases glutaminolysis and
diminishes mitochondrial mass of cancer cells both in vitro and in vivo, thereby
severely suppressing cancer bioenergetics and metabolism. As a result, a high
level of 14-3-3σ in tumors is strongly associated with increased breast cancer
patients’ overall and metastasis-free survival as well as better clinical outcomes.
Thus, this study reveals a new role for 14-3-3σ as a significant regulator of
cancer bioenergetics and a promising target for the development of anti-cancer
metabolism therapies.
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GRAPHICAL ABSTRACT

Figure 1
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Figure 1. 14-3-3σ suppresses cancer glycolysis, glutaminolysis and
mitochondrial biogenesis by targeting c-Myc. Glycolysis, glutaminolysis and
mitochondrial biogenesis are essential metabolic alterations for cancer cells
because they provide not only the necessary energy but also vital metabolites for
rapid cell division and large-scale biosynthesis, for instance amino acid, lipid,
nucleotide syntheses. Therefore, these metabolic processes are important for
tumor growth, survival, proliferation, metastasis and resistance to anti-cancer
therapies. Myc has been characterized as a main driver of these three metabolic
pathways. In fact, Myc induces the expression of many target genes that are
crucial for glycolysis, glutaminolysis and mitochondrial biogenesis. On the other
hand, 14-3-3σ is a tumor suppressor that is directly transactivated by p53. In this
study, we find that 14-3-3σ suppresses glycolytic pathway, reduces
glutaminolysis and decreases mitochondrial mass in cancer cells by promoting
the ubiquitination and degradation of Myc. Furthermore, metabolomics analysis
additionally suggests that 14-3-3σ may also control phospholipid metabolism, as
well as nucleotide and amino acid biosynthesis, which indicates a broad impact
of 14-3-3σ on cancer metabolism. Thus, 14-3-3σ severely affects cancer
bioenergetics and may ultimately decrease tumor growth, survival, proliferation,
metastasis as well as resistance to anti-cancer therapies.

	
   x	
  

TABLE OF CONTENTS
DEDICATION………………………………………………………………….……….iii
ACKNOWLEDGEMENTS…………………………………………….………………iv
ABSTRACT……………………………………………………………………………viii
GRAPHICAL ABSTRACT..……………………………………………………….….ix
TABLES OF CONTENTS………………………………………………………….…xi
LIST OF FIGURES…………………………………………………………...….……xv
LIST OF TABLES………………………………………………………….…………xix
LIST OF ABBREVIATIONS……………………………………………………...…..xx

CHAPTER 1. INTRODUCTION………………………………………………………1
1.1 Cancer metabolic reprogramming……………………...……………1
a. Cancer glycolysis………………………………………………..1
b. Glutaminolysis…………………………………………………..12
c. Mitochondrial biogenesis………………………….…………..14
1.2 Myc…………………………………………………………….……..…...18
1.3 14-3-3σ…………………...……………………………………………….24
1.4 Rationale and hypothesis…………………………………………….34

CHAPTER 2. MATERIALS AND METHODS………………………………………35
2.1 Tissue Culture………………………………………………………...…35
2.2 Western Blot analysis………………………………………………….35
	
   xi	
  

2.3 Lactate production and glucose consumption assay……………36
2.4 Establishment of retroviral Tet On 14-3-3σ system………………36
2.5 Experiment plan for microPET scan and 13C-pyruvate MRSI…...37
2.6 Glucose uptake assay and microPET Scan……………………......40
2.7 Hyperpolarized 13C-pyruvate MRSI……………………………….....40
2.8 Measurement of ECAR and OCR…………………………………….42
2.9 Metabolomics analysis by NMR……………………………………...44
2.10 Realtime PCR…………………………………………………………..44
2.11 Dual Luciferase Reporter Assay……………………………………47
2.12 Lentiviral shRNA………………………………………………………47
2.13 Bioinformatics analysis……………………………………………...48
2.14 Immunohistochemistry staining.....………………………………..48
2.15 Supplemental Information…………………………………………...49
2.16 Biostatistics analysis…………………………………………………50

CHAPTER 3. RESULTS……………………………………………………………...51
3.1 High 14-3-3σ expression is associated with good clinical
outcomes and negatively correlated with Myc-induced metabolic
genes expression in breast cancer patients………………………........51

3.2 Loss of 14-3-3σ leads to an increase in glucose consumption and
glucose uptake in cancer cells…………………………………………….72

	
  xii	
  

3.3 14-3-3σ suppresses lactate production and decreases ATP
concentrations in cancer cells…………………………………………….83

3.4 14-3-3σ promotes Myc ubiquitination, increases the turnover rate
of Myc, suppresses Myc transcriptional activity, and decreases Mycinduced glycolytic target genes expression…………………………….98

3.5 14-3-3σ regulates glutaminolysis and mitochondrial biogenesis
by controlling Myc transcriptional activity……………………….……116

3.6 The regulation of cancer metabolism by 14-3-3σ is via targeting
Myc and does not require p53 impact………………………………..…134

3.7 14-3-3σ suppresses cancer glycolysis, glutaminolysis and
mitochondrial biogenesis in vivo……………………………………..…142

CHAPTER 4. DISCUSSIONS………………………………………………………152
4.1 Lack of 14-3-3σ enhances glucose uptake in cancer cells……..153

4.2 14-3-3σ increases Myc degradation and suppresses Myc
transcriptional activity……………………………………………………..153

4.3 14-3-3σ deficiency may facilitate tumor energy metabolism,

	
  xiii	
  

cancer metastasis and progression…………………………………….157

4.4

14-3-3σ

suppresses

cancer

glutaminolysis,

mitochondria

biogenesis and may affect amino acids, phospholipids and
nucleotides biosynthesis………………………………………………….159

4.5 Conclusions……………………………………………………………..161

4.6 Future research directions……………………………………………161

CHAPTER 5. REFERENCES………………………………………………………165
CHAPTER 6. VITA…………………………………………………………………..180

	
  xiv	
  

List of Figures
Page
1.

Graphical Abstract

ix

2.

Cancer glycolysis is essential for tumor cells

5

3.

Cancer glycolysis is regulated by Myc, HIF1 and p53

10

4.

The importance of glutaminolysis and mitochondrial biogenesis

16

5.

The important signaling pathways regulated by Myc

19

6.

The domains and motifs of Myc protein

21

7.

14-3-3σ stabilizes p53 and induces cell cycle arrest

26

8.

Domain mapping of 14-3-3σ protein

28

9.

14-3-3σ expression is commonly down-regulated in cancers

30

10.

14-3-3σ expression is frequently down-regulated in metastatic and

invasive breast cancer cell lines

32

11.

The in vivo experiment plan

38

12.

High 14-3-3σ improves breast cancer patients’ survival

52

13.

High 14-3-3σ decreases breast cancer patients’ 18FDG uptake

57

14.

14-3-3σ decreases Myc-induced target gene expression

62

15.

14-3-3σ decreases Myc-induced metabolic target gene expression 64

16.

The negative correlation between 14-3-3σ and Myc-induced metabolic

target gene expression

66

17.

The inverse relationship between 14-3-3σ and TFAM levels

68

18.

The negative correlation between 14-3-3σ and Myc protein level

70

19.

Loss and knockdown of 14-3-3σ lead to an increase in glucose
	
  xv	
  

consumption and uptake
20

73

Restoration of 14-3-3σ expression in 14-3-3σ-deficient cancer cells leads

to decreased glucose consumption

75

21.

Loss of 14-3-3σ increases glucose uptake

77

22.

14-3-3σ expression decreases glucose uptake in HCT116 14-3-3σ-/-

cancer cells
23.

79

14-3-3σ decreases the expression of glucose transporter Glut1 on cellular

membrane

81

24.

Loss of 14-3-3σ increases lactate production

85

25.

14-3-3σ expression decreases cancer lactate production

87

26.

Loss and knockdown of 14-3-3σ elevates ECAR

89

27.

14-3-3σ decreases lactate production

91

28.

14-3-3σ expression decreases lactate production in hypoxia

93

29.

The negative impact of 14-3-3σ on ATP level in cancer cells

96

30.

14-3-3σ promotes c-Myc poly-ubiquitination

99

31.

14-3-3σ increases Myc turnover rate

101

32.

14-3-3σ decreases Myc transactivational activity

104

33.

Loss and knockdown of 14-3-3σ increases the expression of Myc-induced

glycolytic target genes
34.

106

Loss and knockdown of 14-3-3σ increase the expression of Myc-induced

glycolytic target genes in hypoxic condition

	
  xvi	
  

108

35.

14-3-3σ down-regulates Myc-induced glycolytic target genes expression

both in normoxic and hypoxic conditions
36.

110

Loss and knockdown of 14-3-3σ increase Myc-induce glycolytic target

genes expression at protein level
37.

112

Doxycycline-induced 14-3-3σ decreases protein level of Myc-targeted

glycolytic genes

114

38.

14-3-3σ suppresses oxygen consumption

118

39.

Induction of Flag-14-3-3σ decreases Oxygen Consumption Rate

120

40.

14-3-3σ expression down-regulates Myc target genes involved in

glutaminolysis
41.

123

14-3-3σ decreases ammonia production and down-regulates Glutaminase

1 protein expression

125

42.

Loss of 14-3-3σ significantly increases mitochondrial mass

128

43.

14-3-3σ expression decreases mitochondrial mass

130

44.

14-3-3σ

induction

decreases

mitochondrial

gene

biogenesis
45.

and

132

c-Myc knockdown compromises 14-3-3σ-mediated down-regulation of

ECAR and OCR
46.

expression

136

Lack of p53 doesn’t hinder 14-3-3σ’s ability to suppress ECAR and OCR
138

47.

Lack of p53 doesn’t prevent the negative impact of 14-3-3σ on cancer

metabolism and Myc-induced glycolytic target gene expression

140

48.

144

14-3-3σ suppresses cancer glycolysis in vivo

	
  
xvii	
  

49.

The negative impact of 14-3-3σ on Myc-targeted glycolytic genes

expression in vivo

146

50.

14-3-3σ decreases glutaminolysis & mitochondrial biogenesis in vivo 148

51.

14-3-3σ suppresses pyruvate-to-lactate conversion in xenografted breast

tumors

150

52.

The mechanism of 14-3-3σ-enhanced Myc poly-ubiquitination

155

53.

The broad negative impact of 14-3-3σ on cancer metabolism

163

	
  
xviii	
  

List of Tables
1.

Demographic and clinical information of breast cancer patient cohort

analyzed in Figure 12

54

2.

14-3-3σ’s expression is frequently low in high-grade breast tumors

55

3.

14-3-3σ’s expression is inversely correlated with18FDG PET Standardized

Uptake Value in breast cancer patients’ tumors

	
  xix	
  

59

List of Abbreviations
2-NBDG

2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose

ACTB

Beta actin

Ad-14-3-3σ

Adenovirus carrying 14-3-3σ gene

Ad-βgal

Adenovirus carrying beta galactosidase gene

ADP

Adenosine diphosphate

ASCT2

Anti-Neutral amino acid transporter 2 (synonym of SLC1A5)

ATCC

American Type Culture Collection

ATP

Adenosine triphosphate

BCL-2

B-cell Chronic lymphocytic leukemia/lymphoma 2

BCL-XL

BCL2-like 1

CAD

Carbamoyl-phosphate synthetase 2

CDC2 or CDK1

Cyclin-dependent kinase 1

CDK2

Cyclin-dependent kinase 2

cDNA

complementary deoxyribonucleic acid

Chx

Cycloheximide

CI

Confidence interval

CMV

Cytomegalo virus

CMV/TO

Cytomegalo virus / Tetracycline Repressor Operator

DHFR

Dihydrofolate reductase

DMEM

Dulbecco's Modified Eagle Medium

DMSO

Dimethyl sulfoxide

	
  xx	
  

DNA

Deoxyribonucleic acid

DNP

Dynamic nuclear polarisation

DSB

Double strand break

ECAR

Extracellular Acidification Rate

ENO1

Enolase 1

FADH2

reduced flavin adenine dinucleotide

FCCP

Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone

FDG

Fluorodeoxyglucose

GAPDH

Glyceraldehyde 3-phosphate dehydrogenase

GLS1

Glutaminase 1

GPI

Glucose-6-phosphate Isomerase

GSEA

Gene Set Enrichment Analysis

HIF1A

Hypoxia-inducible factor 1

HK2

Hexokinase 2

HLH

Helix-loop-helix

ID

inner diameter

IHC

Immunohistochemistry

IKK

I-kappa-B kinase

kPL

rate constant of 13C pyruvate-to-13C lactate reaction

LDHA

Lactate Dehydrognease

LPL

Lipoprotein lipase

LZ

Leucine zipper

	
  xxi	
  

MDACC

M.D. Anderson Cancer Center
Murine double minute 2, p53 E3 ubiquitin protein ligase

MDM2
homolog (mouse)
miR

micro RNA

MrDb or DDX18

DEAD (Asp-Glu-Ala-Asp) box polypeptide 18

MRI

Magnetic Resonance Imaging

mRNA

messenger ribonucleic acid

MRSI

Magnetic Resonance Spectroscopy Imaging

MT-CO1

mitochondrial cytochrome c oxidase I

MT-ND1

NADH dehydrogenase

mtDNA

mitochondrial DNA

NAD

nicotinamide adenine dinucleotide

NAO

10-Nonyl Acridine Orange

NDAH

reduced nicotinamide adenine dinucleotide

NDAPH

reduced nicotinamide adenine dinucleotide phosphate

NF-κB

Nuclear Factor KB

NIMA

(never in mitosis gene a)-related kinase 1

NMR

Nuclear Magnetic Resonance

NP-40

Nonidet P40

OCR

Oxygen Consumption Rate

PARP-1

poly(ADP-ribose) polymerase

PDH

Pyruvate Dehydrogenase

	
  
xxii	
  

PDK1

Pyruvate Dehydrogenase Kinase

PET

Positron Emission Tomography

PET SUV

Positron Emission Tomography Standardized Uptake Value

PFK1

Phosphofructose kinase 1

PFK2

Phosphofructose kinase 2

PGK1

Phosphoglycerate kinase 1

PGM1

Phosphoglucomutase-1

Pi

inorganic Phosphate

Pin1

peptidylprolyl cis/trans isomerase, NIMA-interacting 1

PKM2

Pyruvate Kinase M2 isoform

PPP

Pentose phosphate pathway

PPRC1

Peroxisome proliferator-activated receptor gamma

qRT-PCR

quantitative Realtime Polymerase Chain Reaction

RCC1

Regulator of chromosome condensation 1

RNA

Ribonucleic acid

SCO2

Synthesis of cytochrome c oxidase-2

shRNA

short hairpin ribonucleic acid

SLC1A5 or ASCT2

Solute carrier family 1 (neutral amino acid transporter),
member 5 [Homo sapiens]

SLC2A1 or Glut1

Solute carrier family 2 (facilitated glucose transporter), member 1

SLC2A2 or Glut2

Solute carrier family 2 (facilitated glucose transporter), member 2

SLC2A3 or Glut3

Solute carrier family 2 (facilitated glucose transporter), member 3

	
  
xxiii	
  

SLC2A4 or Glut4

Solute carrier family 2 (facilitated glucose transporter), member 4

SN2 or SLC38A5

Solute carrier family 38, member 5 (a high-affinity
glutamine importer)

TCA

Tricarboxylic Acid cycle

TERT

Telomerase Reverse Transcriptase

TetR BSR

Tetracycline Repressor - Blasticidine Resistance Fusion Protein

TFAM

Transcription Factor A, Mitochondrial

TIGAR

TP53-induced glycolysis and apoptosis regulator

TK

Thymidine kinase 1, soluble

TPI

Triosephosphate isomerase 1

wt

wild type

α-KG

alpha ketoglutarate

	
  

	
  
xxiv	
  

Chapter 1. Introduction

1.1 Cancer metabolic reprogramming
Cancer metabolic reprogramming has been shown to be a major emerging
hallmark of cancer providing tumor cells with significant advantages in proliferation,
growth, metastasis, survival and resistance to anti-cancer therapies (Hanahan and
Weinberg, 2011; Yeung et al., 2008). Among the most significant alterations of cancer
cells bioenergetics, increase in glycolysis, glutaminolysis and mitochondrial biogenesis
is essential for tumor formation and progression. These metabolic processes are crucial
because they provide not only energy but also important metabolites to support largescale biosynthesis and rapid proliferation of tumor cells.(Dang, 2010a; Hanahan and
Weinberg, 2011; Wallace, 2012; Yeung et al., 2008).

a. Cancer glycolysis
Glycolysis is an important cellular metabolic process that sequentially
catabolizes D-glucose (C6H12O6) into pyruvate (CH3COCOO-). Glycolysis includes 10
sequential reactions that produce 10 intermediate metabolites. The energy from
glycolysis is used to produce ATP (adenosine triphosphate) and also NADH (reduced
nicotinamide adenine dinucleotide). The general reaction of glycolysis is listed as below:
C6H12O6 + 2 NAD+ + 2 ADP + 2 Pi  2 CH3COCOO- + 2 NADH + 2 H+ + 2 ATP + 2 H2O

There is a significant difference between normal and tumor cells regarding their
preference for glycolysis. In aerobic conditions, normal cells prefer mitochondrial
1	
  

oxidative phosphorylation. These healthy cells use glycolysis to convert glucose to
pyruvate and then to Acetyl-CoA to fuel the Tricarboxylic Acid Cycle (TCA cycle) and
electron transport chain in mitochondria. Only under hypoxic conditions, glycolysis is
prioritized and most of pyruvate is processed to lactate in healthy cells. Interestingly, in
1930 and 1956, the Nobel Laureate Otto Warburg reported that even in the presence of
ample amount of oxygen, cancer cells preferentially utilized glycolysis rather than
mitochondrial respiration (Warburg, 1930, 1956a, b). In addition, most of pyruvate
produced from glycolysis is converted to lactate in the cytosol rather than to Acetyl-CoA.
This phenomenon is aerobic glycolysis and often referred as the Warburg effect
(Hanahan and Weinberg, 2011; Yeung et al., 2008).

To compensate for the 18-fold lower ATP production yield by glycolysis
compared to mitochondrial oxidative phosphorylation, cancer cells frequently upregulate
glucose transporters, especially Glut1 (SLC2A1), which significantly increases glucose
uptake into cytosol. Cancer cells also increase the expression of glycolytic enzymes to
speed up the glycolytic rate. In some cases, malignant fast growing cells may have a
glycolytic rate that is 200 times faster than that of normal tissue of the same origin
(DeBerardinis et al., 2008a; Hsu and Sabatini, 2008; Jones and Thompson, 2009; Wise
et al., 2008). In fact, this substantial elevation in glucose import and usage has been
found in many cancer types and is the basis for Positron Emission Tomography (PET)
Scan with 18Fluorodeoxyglucose, a radio-labeled glucose analog, to visualize tumors.

The shift from an oxidative to a glycolytic metabolism in cancer cells confers a

2	
  

significant survival advantage under hypoxic and harsh conditions. In fact, since
glycolysis does not require oxygen, this metabolic pathway enables cancer cells to
survive hypoxia, which occurs frequently in solid tumors. Furthermore, by shifting to
glycolysis, cancer cells are able to suppress apoptosis, promote cell division,
radio/chemotherapy resistance, and facilitate invasion (Gatenby and Gillies, 2004;
Hanahan and Weinberg, 2011; Yeung et al., 2008). In addition, glycolysis with
upregulated Lactate Dehydrogenase A (LDHA) also facilitates the conversion of
pyruvate to lactate, which significantly reduces oxidative stress because there is less
pyruvate entering mitochondria for oxidative phosphorylation (Bonnet et al., 2007; Chen,
1988). Moreover, lactate produced by cancer glycolysis is released into tumor
microenvironment, lowers pH and promotes the breaking down of Extra Cellular Matrix,
thereby facilitating cancer cell invasion and metastasis. Secreted lactate is also used by
other neighboring cancer cells as their main energy source via the TCA cycle (Feron,
2009; Kennedy and Dewhirst, 2010; Semenza, 2008).

Interestingly, over-expression of Hexokinase 2, a glycolytic enzyme that
catalyzes the phosphorylation of glucose into glucose-6-phosphate, significantly
suppresses apoptosis by preventing cytochrome c release from mitochondria (Pastorino
et al., 2005). More importantly, increased glycolysis enables the diversion of glycolytic
metabolites into many other important biosynthetic pathways to generate nucleotides,
nicotinamide adenine dinucleotide phosphate (NADPH), amino acids and other
macromolecules that are important for cell growth and division (Potter, 1958; Vander
Heiden et al., 2009; Yeung et al., 2008). Notably, elevated glycolysis is also present in

3	
  

stem cells, which suggests a role of this metabolic pathway in promoting survival and
proliferation of cancer progenitors (Hanahan and Weinberg, 2011).

Glycolytic metabolism is also crucial for cancer cells to survive and resist anticancer therapies. In fact, glycolysis promotes the production of NADPH by fueling
pentose phosphate pathway (Mazurek et al., 1997). NADPH is an important reducing
factor that is crucial for cytochrome P-450-mediated drug detoxification. Moreover,
glycolytic pathway also regenerates NAD+ that is essential for DNA damage repair. In
this reaction, poly(ADP-ribose) polymerase (PARP-1) breaks down NAD+ into ADPribose and nicotinamide. Then, ADP-ribose is further polymerized by PARP-1 and
transferred to nuclear proteins. Therefore, PARP-1 activation uses a large amount of
NAD+ to repair DNA damage (Ying et al., 2005). In addition, ATP from glycolysis is also
an important material for DNA reparation and a major energy source for Multi Drug
Resistance 1 to discard toxic chemotherapeutic agents (Yeung et al., 2008).
In addition to generating ATP, glycolysis supplies cancer cells with important
precursors for crucial biosynthetic pathways. For example, glucose-6-phosphate of
glycolysis can fuel pentose phosphate pathway for subsequent nucleotide synthesis, an
important

process

required

for

cell

proliferation

(Hsu

and

Sabatini,

2008).

Dihydroxyacetone phosphate, another glycolysis intermediate, can be converted to
glycerol-3-phosphate to form triglycerides and lipids (Gruning et al., 2011; Wallace,
2012).
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Figure 2. Cancer glycolysis is essential for tumor cells. Increased glycolysis has
been shown to be a common and very important feature of cancer bioenergetics. In fact,
this metabolic pathway provides cancer cells with energy and metabolites to support cell
growth, proliferation, biosynthesis and metabolism. In addition, glycolysis significantly
increases survival, promotes metastasis and enhances resistance to anti-cancer
therapies.
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At the molecular level, aerobic glycolysis in cancer cells has been shown to be
driven by activated oncogenes as Myc, HIF1a, Ras and suppressed by tumor
suppressors, e.g., TP53 (DeBerardinis et al., 2008a; Deberardinis et al., 2008b; Jones
and Thompson, 2009; Yeung et al., 2008). The important role of Myc in inducing aerobic
glycolysis has been well documented in many studies. Hexokinase 2 (HK2),
Phosphatefructose Kinase (PFK1), Glucose-6-phosphate Isomerase (GPI), Enolase 1
(ENO1), Lactate Dehydrogenase A (LDHA) and glucose transporter Glut1 (SLC2A1) are
direct targets of Myc. Conserved canonical E box (5’-CACGTG-3’) has been found in
31-111 base pair islands of ENO1, HK2, and LDHA. Non-conserved canonical E boxes
also occur in GPI, pyruvate kinase 2 (PKM2), phosphoglycerate kinase 1 (PGK1),
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and triose phosphate isomerase
1 (TPI1). Nuclear run-on and Chromatin Immunoprecipitation assays in multiple
independent studies additionally confirmed the upregulation of these glycolytic enzymes
due to Myc and the binding of Myc to these target genes (Dang, 2009; Kim et al., 2004;
Li et al., 2005; Yeung et al., 2008).

While Myc is important to induce glycolysis in aerobic condition, HIF-1 is the
major driver of glycolysis in hypoxia. Indeed, HIF-1 directly transactivates the majority of
glucose transporters and glycolytic enzymes in hypoxic condition. These glycolytic
genes contain HIF-1 regulatory element (Dang et al., 1997; Dang and Semenza, 1999).
The list of HIF-1 glycolytic targets is presented in Figure 3. Among HIF-1-induced
glycolytic genes, LDHA is crucial for aerobic glycolysis in cancer cells. LDHA catalyzes
the reaction to convert pyruvate to lactate and regenerates NAD+ to accelerate
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glycolytic flux. Lactate is also very important for cancer cell metabolism and metastasis
as discussed above. Another enzyme that is induced by both HIF-1 and Myc is pyruvate
dehyrogenase kinase 1 (PDK1). PDK1 functionally inactivates pyruvate dehydrogenase
by phosphorylation, thereby blocking the biochemical reaction that converts pyruvate to
Acetyl-CoA and facilitating glycolysis (Kim et al., 2007).

In addition to its tumor suppressing ability, p53 is also a major regulator that
controls the balance between glycolysis and mitochondrial oxidative phosphorylation
through inducing two important target genes: TP53-induced glycolysis and apoptosis
regulator (TIGAR) and synthsis of cytochrome c oxidase-2 (SCO2) (Bensaad et al.,
2006; Matoba et al., 2006). TIGAR is a fructose-bisphosphatase-2 that converts
fructose-2,6-bisphosphate to fructose-6-phosphate. Since fructose-2,6-bisphosphate is
a strong allosteric activator of Phosphofructose Kinase 1, an important glycolytic
enzyme, TIGAR expression and activity can significantly slow down glycolytic flux. On
the other hand, SCO2 is critical for cytochrome c oxidase complex of mitochondrial
electron transport chain. ATP from mitochondrial respiration has been shown to inhibit
Hexokinase function, thereby decelerating glycolysis (Matoba et al., 2006).

Furthermore, p53 directly binds to promoter regions of Glut1 and Glut4 to
suppress the transcription of these two glucose transporters, causing a significant
decrease in glucose uptake (Schwartzenberg-Bar-Yoseph et al., 2004). Additionally,
p53 inhibits I-kappa-B kinase (IKK)-mediated NF-κB activation, thereby reducing the
expression

of

Glut3,

an

NF-κB

target
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gene

involved

in

glucose

transport

(Schwartzenberg-Bar-Yoseph et al., 2004).
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Figure 3. Cancer glycolysis is regulated by three master regulators,
Myc, HIF1 and p53. Myc and HIF-1 are strong inducers of glycolysis by transactivating
the majority of glucose transporters and glycolytic enzymes. In contrast, p53 is a
suppressor of this metabolic pathway by elevating the expression of TIGAR, SCO2 and
suppresses the expression of important glucose transporters Glut1, Glut3, Glut4. This
figure is modified from Yeung et al. 2008. The gene names that are printed in green are
the common target genes of Myc and HIF1. Glut2 and Glut4 are only induced by Myc.
b. Glutaminolysis
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b. Glutaminolysis
Beside glycolysis, cancer cells also depend on glutaminolysis. Glutaminolysis is
a multi-step biochemical reaction sequence that converts glutamine into various
metabolites. Glutaminolysis provides tumor cells with not only energy but also carbon
and nitrogen sources to support their large-scale biosynthesis and rapid proliferation
(Dang, 2010a). In fact, glutaminolysis plays a significant role in fueling the Tricarboxylic
Acid (TCA) cycle and mitochondrial respiration. The intermediates of TCA cycle can be
then further used to synthesize amino acids, nucleotides, lipids, and many other
important building blocks to support the accelerated proliferation of tumor cells (Dang,
2010a; DeBerardinis et al., 2007).

Glutaminolysis is crucial for tumor growth and proliferation. In 2008, DeBerardinis
et al. reported that glioma cells had a high rate of glutaminolysis to provide anaplerotic
α-ketoglutarate to fuel the TCA Cycle and mitochondrial respiration, resulting in
increased metabolic intermediates for active lipid, amino acid and nucleotide
biosynthesis (DeBerardinis et al., 2007). The importance of glutaminolysis is also
demonstrated by the multifaceted and key role of glutamine in cancer metabolism. After
being imported into cytoplasm by glutamine transporters, glutamine can be used to
synthesize protein, glucosamine, nucleotide, or converted by mitochondrial glutaminase
(GLS) into glutamate and urea (Dang, 2010a; Wise et al., 2008). Glutamate can be then
processed into α-ketoglutarate through transamination or oxidative deamination
reactions (Dang, 2010a; Meng et al., 2010). In addition, glutamine is also crucial to
activate TOR (target of rapamycin) kinase, a master switch of cell growth (Blommaart et

12	
  

al., 1995; Dann and Thomas, 2006; Fox et al., 1998; Hara et al., 1998; Nicklin et al.,
2009; Xu et al., 1998). The uptake process of essential amino acids also needs
glutamine (Nicklin et al., 2009). Furthermore, glutamine is required to maintain
mitochondrial membrane integrity and potential and is needed to produce NADPH,
which is often used to control redox balance and synthesize macromolecules (Vander
Heiden et al., 2009). Because of the importance of glutamine and glutaminolysis, a
number of cancer cells are addicted to glutamine and this addiction could be exploited
as a therapeutic target for cancer treatment (Wise and Thompson, 2010).

Myc is the primary inducer of glutaminolysis in cancer cells. Indeed, Myc elevates
the expression of Glutaminase 1 (GLS1) by suppressing miR-23a/b, and transactivates
glutamine importers ASCT2 and SN2 (Dang, 2010a; Dang et al., 2009; Gao et al.,
2009). ChIP and quantitative RT-PCR data show that Myc directly induces the
expression of high-affinity glutamine importers ASCT2 and SN2, leading to a significant
influx of glutamine (Dang, 2010a; Dang et al., 2009; Gao et al., 2009).

Interestingly, Myc-induced glutaminolysis renders many cancer cells addicted to
exogenous glutamine as nitrogen and carbon sources for mitochondrial membrane
potential maintenance and biosynthesis. Therefore, glutamine depletion causes
apoptosis and eliminates cancer cells in a Myc-dependent manner (Wise et al., 2008;
Yuneva et al., 2007). This programmed cell death due to glutamine deprivation could be
reversed by overexpressing BCL-2, BCL-XL as well as a dominant negative caspase-9
mutant (Wise et al., 2008; Yuneva et al., 2007). Supplying cancer cells with pyruvate, α-
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ketoglutarate, and oxaloacetate also prevents this cell death, indicating the importance
of glutamine in mitochondrial anaplerosis (Yuneva et al., 2007). In fact, glutamine
deprivation of cancer cells that have a high Myc level results in a significant decrease in
TCA cycle intermediates concentrations. Importantly, excessive glucose abundance still
can’t reverse this reduction, which implies that Myc may abolish the ability of cancer
cells to use glucose for mitochondrial anaplerosis by upregulating LDHA to convert
pyruvate to lactate (Wise and Thompson, 2010; Yuneva et al., 2007). Thus,
glutaminolysis is crucial for cancer cells in terms of energy production and biosynthesis.

c. Mitochondrial biogenesis

In contrast to common thinking, mitochondrial biogenesis is essential for the
tumor cells because mitochondria are the key nexus of the majority of biosynthetic
pathways and energy production. Furthermore, mitochondria also regulate redox status
and Ca2+ concentration (Wallace, 2012). Therefore, lack of mitochondria severely
reduces tumorigenesis, tumor growth and colony formation (Cavalli et al., 1997;
Desjardins et al., 1985; King and Attardi, 1989; Magda et al., 2008; Morais et al., 1994;
Wallace, 2012; Weinberg et al., 2010). Moreover, compared to normal and differentiated
cells, cancer cells reprogram their mitochondria to change from a maximal energy
production by mitochondrial respiration to a balance between energy demands with
large-scale biogenesis and rapid cell division (Wallace, 2012). Therefore, mitochondria
in general and mitochondrial biogenesis in particular are very important for tumor cells.
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It has been well documented that Myc is a major inducer of mitochondrial
biogenesis. Indeed, Myc promotes the expression of many nuclear-encoded
mitochondrial genes and directly transactivating Transcription Factor A, Mitochondrial
(TFAM), a transcription factor that is essential for mitochondrial genes transcription and
mitochondrial DNA replication (Li et al., 2005). Since the synthesis of new mitochondrial
components and mitochondrial DNA is crucial for mitochondrial biogenesis, Myc plays a
critical role in increasing mitochondria number. Consequently, lack of Myc severely
diminishes mitochondrial mass and mitochondrial biogenesis, leading to a negative
impact on many metabolic pathways of cancer cells (Li et al., 2005).
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Figure 4
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Figure 4. Glutaminolysis and mitochondrial biogenesis provide important energy
and metabolites for cancer cells to support tumor growth, survival, proliferation,
metastasis and resistance to anti-cancer therapies. In glutaminolytic pathway,
glutamine is imported into cytoplasm by glutamine transporters, mostly by ASCT2 and
SN2. Glutamine is then converted to glutamate by glutaminase. Glutamate is then
processed into α-ketoglutarate that participates in TCA cycle. TCA cycle generates
NADH and FADH2 that donate electrons to mitochondrial respiratory chain to produce
ATP. In addition, TCA cycle intermediates can also be used to synthesize amino acids,
lipids, nucleotides, sterols, among other important molecules, to support rapid
proliferation of cancer cells. On the other hand, mitochondrial biogenesis is also vital for
cancer cells because mitochondria play a key role in producing energy and synthesizing
many crucial macromolecules and metabolites for cell growth and division. Myc has
been shown to induce glutaminolysis by up-regulating glutaminase, ASCT2 and SN2
expression. Myc also transactivates the genes that encode mitochondrial components.
In addition, Myc induces the expression of Transcription Factor A, Mitochondrial
(TFAM). TFAM bends mitochondrial DNA and facilitates mitochondrial gene
transcription and mitochondrial DNA replication, which is required for mitochondrial
biogenesis. Thus, Myc is an important inducer of both glutaminolysis and mitochondrial
biogenesis that are crucial for cancer cell metabolism.

17	
  

1.2 Myc
c-myc (Myc) is the cellular equivalent of the v-myc oncogene from retroviruses
(Bishop, 1982, 1985; Bishop et al., 1978; Bister and Jansen, 1986; Sheiness et al.,
1978). The proto-oncogene c-myc is a member of myc family consisting of L-myc, Bmyc, N-myc, and s-myc. Nevertheless, c-myc, L-myc, and N-myc are the only isoforms
that induce aberrant proliferation (Facchini and Penn, 1998; Henriksson and Luscher,
1996; Lemaitre et al., 1996; Marcu et al., 1992; Spencer and Groudine, 1991). Deletion
of c-myc results in embryonic lethality, indicating the essential role of c-myc in
development and survival (Davis et al., 1993).
Myc is an important transcription factor regulating multiple essential signaling
pathways

(Dang,

1999;

Yeung

et

al.,

2008)

(Figure

5).

Myc

contains

a

transactivation/repression domain in its N-terminus as well as a helix-loop-helix leucine
zipper (HLH/LZ) domain at the C-terminus (Figure 6). The canonical DNA binding site of
Myc is 5′-CACGTG-3′ but Myc can also bind to non-canonical sequences to
transactivate or suppress its target genes expression (Blackwell et al., 1993; Blackwell
et al., 1990; Prendergast and Ziff, 1991). By dimerizing with Max, Myc transactivates its
target genes. Myc is also able to repress transcription by associating with other
transcriptional activators, for instance Miz-1 (Amati, 2004). On the other hand, Myc is
frequently overexpressed in many human cancers. Myc is a major oncogenic
transcription factor that can induce tumorigenesis by promoting cell proliferation,
causing genome instability, and blocking cell differentiation (Adhikary and Eilers, 2005).
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Figure 5. Myc plays an important role in controlling multiple essential cellular
processes, for instance cell cycle progression, apoptosis, DNA dynamics, DNA
synthesis, energy metabolism, and biosynthesis of macromolecules. This figure is
modified from Dang, 1999. All full gene names are listed in the List of Abbreviations
(pages xxi – xxv).
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Figure 6. The domains and motifs of Myc protein. TRD: Transcriptional Regulatory
Domain; HLH-LZ: Helix-Loop-Helix/Leucine Zipper motif; b: basic region; NTS: nuclear
target signal.
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In particular, it has been well documented that Myc is a strong inducer of
important metabolic alterations in cancer cells (Dang, 2010a; Dang et al., 2009; Li et al.,
2005; Yeung et al., 2008). Indeed, Myc is one of the master regulators that remarkably
upregulates the majority of glycolytic genes, thereby promoting glucose consumption
and glycolysis (Dang, 2010b; Yeung et al., 2008). The upregulation of these glycolytic
enzymes is due to Myc binding to its target genes for transcriptional activation (Dang et
al., 2009; Kim et al., 2004; Li et al., 2005; Yeung et al., 2008). Myc also elevates the
expression of glutaminase and glutamine transporters ASCT2 and SN2, thereby
increasing glutaminolysis in cancer cells (Dang, 2010a, b). Moreover, Myc stimulates
mitochondrial biogenesis by up-regulating the expression of TFAM and mitochondrial
components (Li et al., 2005). On the other hand, Myc also induces the expression of
important genes involved in nucleotide synthesis and amino acid transport (Dang et al.,
1997). Thus the broad impact of Myc on multiple metabolic pathways makes Myc one of
the master regulators of cancer metabolism and gives the Myc-highly-expressing cancer
cells the ability to effectively adapt to various conditions and the versatility to use
different nutrient sources to support rapid tumor growth, proliferation and metastasis.
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1.3 14-3-3σ
14-3-3σ has been widely known for its function in cell cycle regulation and
apoptosis. This protein is a unique member of 14-3-3 family, which consists of 7
members (Benzinger et al., 2005a; Benzinger et al., 2005b). While other 14-3-3 family
members form both hetero and homo-dimers, 14-3-3σ has a strong preference in
forming homo-dimers. In addition, compared to other 14-3-3 isoforms, 14-3-3σ contains
a different C terminus structure, which allows it to associate with a distinct set of
interacting partners (Benzinger et al., 2005b; Wilker et al., 2005).
It is notable that 14-3-3σ is a phospho Serine/Threonine binding protein with two
consensus binding motifs RxxpSxP and RxxxpSxP (Benzinger et al., 2005a; Benzinger
et al., 2005b) that are found on the C terminus of c-Myc. This implies a potential
physical interaction between 14-3-3σ and c-Myc. The binding of 14-3-3σ to its
interacting partners often results in significant changes in stability, localization,
interaction and activity of these target proteins (Lee and Lozano, 2006; Verdoodt et al.,
2006).
Among 14-3-3 family members, only 14-3-3σ is induced by p53 after DNA
damage (Hermeking et al., 1997). After being induced by p53, 14-3-3σ generates a
positive feed back loop by protecting p53 from MDM2-mediated ubiquitination and
degradation. 14-3-3σ sequesters MDM2 to cytoplasm and promotes MDM2 selfubiquitination.

In

addition,

14-3-3σ

also

enhances

p53

tetramerization

and

transactivational activity (Yang et al., 2003; Yang et al., 2007). 14-3-3σ is also known to
cause cell cycle arrest at G1 phase by inhibiting CDK2/CyclinE, and at G2 phase by
sequestering CDC2/CyclinB (Lee and Lozano, 2006).
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14-3-3σ is commonly down-regulated in many common types of cancer. This loss
can be caused either by excessive methylation of the promoter region of 14-3-3σ gene
(Ferguson et al., 2000) or by enhanced ubiquitin-mediated degradation of 14-3-3σ (Choi
et al., 2011; Urano et al., 2002). The loss of 14-3-3σ expression provides a growth
advantage to cancer cells and leads to poor prognosis (Lee and Lozano, 2006), as 143-3σ has been demonstrated to have tumor suppressive qualities (Yang et al., 2006;
Yang et al., 2003).

In spite of all this information, how 14-3-3σ suppresses tumorigenesis is not fully
understood and whether 14-3-3σ involves in the regulation of cancer metabolism
remains unknown. In this study, we demonstrate that 14-3-3σ is a strong inhibitor of
cancer glycolysis, glutaminolysis and mitochondrial biogenesis by promoting Myc
degradation. Thus, our data not only provides an additional insight into the regulation of
cancer metabolism but also discovers a new function of the potent tumor suppressor
14-3-3σ and holds the potential to unlock a door to the development of anti-cancer
metabolism therapies.

25	
  

DSB%

Adapted%from%Lee%
and%Lozano%2006%

Promote%degrada?on%

MDM2%

p53%

En
Pr ha
om nc
ot e%n
e%s uc
el lea
f( u r %
bi exp
qu o
i? rt%
na %
?o
n%

14(3(3σ%

%%%Cyclin%B% CDC2%

Enhance%nuclear%export%
Inhibit%kinase%ac?vity%

CDK2%
%%%Cyclin%E%

Enhance%nuclear%export%
Inhibit%kinase%ac?vity%

G1%phase%arrest%6"

G2%phase%arrest%

Figure 7

26	
  

Figure 7. 14-3-3σ stabilizes p53 and induces cell cycle arrest. Upon DNA damage
or double strand break (DSB), p53 is activated. p53 directly transactivates 14-3-3σ. 143-3σ exerts a positive feedback stabilizing p53 by causing MDM2 nuclear export and
enhancing MDM2 self-ubiquitination. 14-3-3σ also promotes the nuclear export of
CyclinB/CDC2 and CDK2/Cyclin E complexes. 14-3-3σ suppresses kinase activity of
CDK2 and CDC2. As a result, cell cycle progression will stop at G1 and G2 phases
when 14-3-3σ is transactivated.
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Figure 8. Domain mapping of 14-3-3σ protein. 14-3-3σ contains 9 helices, 1 strand
and 2 turns in its structure. 14-3-3σ uses its N-terminus to form homo-dimers and its Cterminus to interact with its partners. 14-3-3σ is a phosphoserine/phosphothreonine
binding protein. The unique structure of 14-3-3σ C-terminus enables 14-3-3σ to interact
with a distinct set of target proteins compared to other 14-3-3 family members.
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Figure 9. 14-3-3σ expression is commonly suppressed in many common cancers.
14-3-3σ level was determined by analyzing transcriptomics profiles of cancer patients
that were retrieved from public databases such as Oncomine, The Cancer Genome
Atlas, Gene Expression Omnibus. For each type of cancer, N indicates the number of
patients included in our analysis. The patients that have more than 60% decrease in 143-3σ mRNA expression level compared to corresponding normal tissues were
considered as having 14-3-3σ down-regulation.
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Figure 10
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Figure 10. 14-3-3σ expression is frequently down-regulated in metastatic (orange
printed) and invasive (blue printed) breast cancer cell lines. MCF10A, MCF10F,
MCF12A are non-tumorigenic epithelial cells having high level of 14-3-3σ. MCF-7, MDAMB-231, MDA-MB-361, MDA-MB-435, MDA-MB-436, MDA-MB-453 and SKBR3 are
metastatic breast cancer cell lines with very low 14-3-3σ expression. BT474, BT549,
HBL-100 and Hs578T are invasive breast carcinoma cell lines with low 14-3-3σ
amounts. BT20, BT483, T47D, ZR-75-1, and 11-9-1-4 are weakly invasive breast
carcinoma cell lines that have moderate or abundant 14-3-3σ presence. The high level
of 14-3-3σ in early/non-invasive breast cancer cells and down-regulation of 14-3-3σ in
advanced, metastatic and invasive breast cancer cells suggest the role of 14-3-3σ as a
checkpoint that cancer cells need to bypass during tumorigenesis.
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1.4 Rationale and hypothesis:
Our transcriptomics analysis and tissue micro array screening of more than 700
tumors from breast cancer patients indicated an inverse correlation between 14-3-3σ
level and metabolic enzymes expression, which suggests a role of 14-3-3σ in controlling
cancer metabolism. Furthermore, our previous studies showed that 14-3-3σ decreased
c-Myc stability while increasing p53 expression (Wen et al., 2012; Yang et al., 2003).
Since c-Myc and p53 are two major regulators of cancer bioenergetics, these
observations prompt us to hypothesize that 14-3-3σ may play an important role in
regulating essential cancer energy metabolic pathways that are controlled by cMyc and p53, such as glycolysis, glutaminolysis and mitochondrial biogenesis.
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Chapter 2. Materials and Methods

2.1 Tissue Culture
MDA-MB-231, MDA-MB-435, T47D, MCF10A, H1299 cancer cell lines were
pruchased from the ATCC (Manassas, VA, USA) and grown in DMEM High glucose
medium which is supplemented with 10% fetal bovine serum (FBS) (Sigma-Aldrich,
Atlanta Biologicals), 2 mM L-glutamine (Cellgro, Manassas, VA) as well as 1%
antibiotic-antimycotic solution (Invitrogen, Grand Island, NY). HCT116 wt, 14-3-3σ-/-,
and p53-/- colon cancer cells (a kind gift from Dr. Bert Vogelstein’s Lab) were also
cultured in DMEM High glucose medium containing 10% fetal bovine serum (SigmaAldrich, Atlanta Biologicals), 2 mM L-glutamine from Cellgro (Manassas, VA) and 1%
antibiotic-antimycotic solution from Invitrogen (Grand Island, NY). All cells were grown
in humidified 37oC incubator with 5% CO2. MDA-MB-231, MDA-MB-435, HCT116 wt,
14-3-3σ-/-, p53-/- cell lines that carry a Tet On Flag-14-3-3σ system were grown in
DMEM High glucose medium containing 10% Tetracycline-free fetal bovine serum
(Atlanta Biologicals), 2 mM L-glutamine from Cellgro (Manassas, VA) and 1% antibioticantimycotic solution from Invitrogen (Grand Island, NY).

2.2 Western Blot analysis
Cells were lysed using a standard lysis buffer containing NP-40 and 0.1%
TritonX-100. The antibodies used were: from Sigma-Aldrich: anti-Flag, anti-Actin; from
Cell Signaling: anti-Hexokinase 2, anti-Aldolase, anti-Pyruvate Kinase M2, anti-Lactate
Dehydrogenase A, anti-Pyruvate Dehydrogenase Kinase 1, anti-Enolase 1, anti-
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Glutaminase; from Novus Biologicals: anti-Phosphofructose Kinase 1, from Fitzgerald
International Industry: anti-14-3-3σ; from Abcam and Epitomics: anti-c-Myc.

2.3 Lactate production and glucose consumption assays
Lactate concentration was measured with an Accutrend Lactate Analyzer
(Roche). Glucose consumption was determined by measuring the difference in glucose
concentrations at the beginning and the end of experiments. Glucose level was
quantified using a Freestyle Glucose Meter (Abbott). Lactate production and glucose
consumption were normalized to final cell number and culture time.

2.4 Establishment of retroviral Tet On 14-3-3σ system
Flag-14-3-3σ cDNA was amplified by PCR from a pCMV5-Flag-14-3-3σ plasmid
in Dr. Lee’s lab and cloned into a pRetro-CMV/TO retroviral plasmid (kindly provided by
Dr. Staudt’s lab, National Cancer Institute (NCI)). After sequence verification, the
pRetro/CMV-TO-Flag-14-3-3σ plasmid was co-transfeted with VSVg and Gag/Pol
plasmids into 293T cells to produce 14-3-3σ Tet On retroviruses. Tet Repressor
retroviruses were produced from the 293T cells after co-transfection of p-BMN-TetRBSR, VSVg and Gag/Pol plasmids (kindly provided by Dr. Staudt’s lab, NCI).
Target cells were first infected with TetR-BSR retroviruses and then selected with
a medium containing 20 µg/ml Blasticidin for 1 week. After that, the cells were infected
with retroviruses carrying Flag-14-3-3σ and followed by a selection with 5 µg/ml
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Puromycin for 1 week. Target cells with established Tet On Flag-14-3-3σ system were
maintained in a regular medium containing 10% Tetracycline-free fetal bovine serum, 2
µg/ml Puromycin, 10 µg/ml Blasticidin, 2 mM L-glutamine and 1% antibiotic-antimycotic
solution. To induce 14-3-3σ’s expression in vitro, Doxycycline (a stable derivative of
Tetracycline) was added to the culture medium at final concentration of 5 ng/ml for 48
hours. To induce 14-3-3σ’s expression in vivo, Doxycycline was added to drinking water
at a final concentration of 200 µg/ml of Doxycycline for 2 weeks. Drinking water that
contains Doxycycline was replaced every 48 hours because of the short half-life of
Doxycycline.

2.5 Experiment plan for microPET Scan and hyperpolarized

13

C-pyruvate-based

Magnetic Resonance Spectroscopy Imaging to examine the impact of 14-3-3σ on
glucose uptake and pyruvate-lactate flux in vivo.
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Figure S5 (related to Figure 7)
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Figure 11. The in vivo experiment plan to study the impact of 14-3-3σ on cancer
metabolism. 1x106 MDA-MB-231 TetR 14-3-3σ cells were injected into mammary fat
pad of each 7-week old female nude mouse. Tumor growth was monitored for 4 weeks.
All mice were then divided into two groups with 5-10 mice in each group. The
experimental group received drinking water containing 200 µg/ml Doxycycline for 2
weeks to induce Flag-14-3-3σ expression in the xenografted breast tumors. The control
group received normal drinking water. The 1st batch of mice with both the control and
experimental groups were subjected to a microPET Scan with 18FDG to measure the
negative impact of 14-3-3σ on glucose uptake in vivo. Similarly, the 2nd batch of mice
with both the control and experimental groups were imaged with hyperpolarized 13Cpyruvate-based Magnetic Resonance Spectroscopy Imaging (MRSI) to evaluate the
suppressive influence of 14-3-3σ on pyruvate-lactate flux in xenograft tumors. All tumors
were extracted after imaging and used for further analyses.
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2.6 Glucose uptake assay and microPET Scan
Glucose uptake in cells was examined using (2-(N-(7-nitrobenz-2-oxa-1,3-diazol4-yl)amino)-2-deoxyglucose (2-NBDG)), a green fluorescent glucose analog, from
Molecular Probes (Invitrogen). Experimental cells were incubated in glucose-free 10%
FBS DMEM containing 120 µM 2-NBDG for 0 minute, 1 minute, 10 minutes, 30 minutes,
1 hour, 2 hours and 3 hours. 2-NBDG uptake was analyzed using a fluorescent
microscope (Olympus) and BD Flow Cytometer.
For glucose uptake in mice, 7-week-old female nude mice carrying MDA-MB-231
TetR 14-3-3σ breast cancer cells were imaged with a Micropet Rodent–R4 scanner 30
minutes after injection with 400 µCi 18FDG according to imaging protocol from the Small
Animal Imaging Facility (SAIF) of M.D. Anderson Cancer Center (MDACC). Tumors
were also visualized with a Burker 7.0 Tesla Magnetic Resonance Imaging (MRI) at
SAIF following SAIF standard imaging procedures.

2.7 Hyperpolarized 13C-pyruvate Magnetic Resonance Spectroscopy Imaging
13

C Hyperpolarization
A mixture containing 20 µL (26 mg) of [1-13C] pyruvic acid (Cambridge Isotopes)

with 15 mM of trityl radical OX063 (GE Healthcare) was combined with 0.6 µL 50mM
Prohance (Bracco Diagnostic Inc.) and polarized using a Hypersense DNP system
(Oxford Instruments). In brief, the solution was frozen to approximately 1.4°K and
irradiated at 94.154 GHz for 45 - 60 minutes in a 3.35T magnetic field (Ardenkjaer-
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Larsen et al., 2003; Golman et al., 2006). When the solid-state polarization reached a
plateau, the solution was dissolved in 4 mL of a heated (180°C) solution containing 80
mM NaOH and 50 mM NaCl.

The final solution containing 80 mM hyperpolarized

pyruvate at a nominal temperature of 37°C and pH of 7.6 was flushed into a receptacle
from which 200 µL was drawn for injection. The injection was administered over 10
seconds beginning within 12 seconds of sample dissolution.

Magnetic Resonance Spectroscopy
Animals were anesthetized using 0.5%-5% isoflurane in oxygen and then placed
on a positioning sled with built-in channels for distribution of anesthesia gases and
circulation of warm water to maintain animal temperature.

All experiments and

procedures involved animals were approved by MD Anderson Cancer Center
Institutional Animal Care and Use Committee. This committee is accredited by the
Association for the Assessment and Accreditation of Laboratory Animal Care
International.
The chemical fate of the hyperpolarized [1-13C]-pyruvate was monitored using a
7T Biospec USR7030 system (Bruker Biospin MRI, Inc) using a dual-tuned 1H-13C
volume coil with 72 mm inner diameter (ID) and a custom-built

13

C surface coil (12 mm

ID) placed over the tumor. Animal position was confirmed using a 3-plane gradientecho proton MRI sequence (TE = 3.6 ms, TR = 100 ms, 30° excitation angle) and the
location of the tumor was confirmed in T2-weighted axial and coronal spin-echo images
(TE = 50ms, TR = 2500ms, 1 mm slice thickness, 4 cm x 3 cm field-of-view encoded
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over a 256 x 192 matrix in 1 mm sections). Field homogeneity was maximized over the
tumor volume using a point-resolved spectroscopy sequence.
For

13

C measurements, a signal was generated by the volume coil and detected

using the surface coil. Dynamic spectra were acquired using a slice-selective singlepulse sequence (SW = 5000 Hz over 2048 points, 10° excitation, 8 mm slice thickness)
that was repeated every 2 seconds for 3 minutes beginning just prior to the injection of
13

C via tail-vein catheter. The spectra were phase-adjusted, and the area under the

spectral peaks corresponding to the C1 of pyruvate and lactate were integrated to
generate curves describing the arrival of hyperpolarized pyruvate and its conversion into
hyperpolarized lactate. These curves were fit to kinetic models that account for chemical
conversion (Harris et al., 2009). The model we used is a modification from the one
described by Harris et al., 2009. Our model had two physical compartments to separate
the effects of tracer circulation, extravasation, and activity. All modeling was performed
using Matlab (The Mathworks) and statistical analysis was performed using GraphPad
Prism 5.0d.

2.8 Measurement of Extracellular Acidification Rate (ECAR) and Oxygen
Consumption Rate (OCR)
Cells and Compounds:
All cancer cell lines with retroviral 14-3-3σ Tet On system such as MDA-MB-231,
HCT116, and H1299 were maintained in a growth medium: DMEM High glucose
supplemented with 10% Tetracycline-free fetal bovine serum, 2 µg/ml Puromycin, 10

42	
  

µg/ml Blasticidin, 2 mM L-glutamine and 1% antibiotic-antimycotic solution. The other
cancer cell lines were maintained in a different growth medium: DMEM High glucose
containing 10% normal fetal bovine serum, 2 mM L-glutamine as well as 1% antibioticantimycotic solution.
Oligomycin (an inhibitor of ATP Synthase) was prepared as 1000X stock at 10
mM in DMSO. FCCP (an ionophore and strong mitochondrial depolarizer) was diluted
as 1000X stock at 5 mM in DMSO. Rotenone (a potent inhibitor of mitochondrial
complex I) and Antimycin A (a strong suppressor of mitochondrial complex III) were
solubilized as 1000X stock at 10 mM in DMSO.
Assay
To measured ECAR and OCR, 3x104 cells from each cell line were seeded per
well of a XF24 microplate 16 hours before the experiment. Right before the Seahorse
XF assay, the cells were changed from a culture medium to an assay medium (lowbuffered DMEM containing 25 mM D-glucose, 1 mM of sodium pyruvate and 1 mM of Lglutamine) and incubated for 1 hour at 37oC. After a baseline measurement, 75 µl of the
above-mentioned inhibitors prepared in assay medium was sequentially injected into
each well to reach the final working 1X concentrations. After 5 minutes of mixing to
equally expose cancer cells to the chemical inhibitors, OCR and ECAR were measured.
OCR was reported in pmole/minute, ECAR was recorded in mpH/minute. Results were
analyzed using Seahorse XF software. Statistical analysis was done with GraphPad
Prism and Sigma Plot programs. OCR and ECAR measurements were normalized to
either final cell number or protein concentration.
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2.9 Metabolomics analysis by Nuclear Magnetic Resonance (NMR)
HCT116 14-3-3σ+/+, HCT116 14-3-3σ-/-, HCT116 14-3-3σ-/- infected with Ad-βgal,
and HCT116 14-3-3σ-/- infected with Ad-14-3-3σ were grown under normal culture
conditions for 48 hours. 20x106 cells per cell line were collected and snap-frozen with
liquid nitrogen. Total metabolites were then extracted from cell pellets using
freezing/thawing extraction and filtration protocols provided by Chenomx Inc. (Alberta,
Canada). Metabolite extracts were then snap-frozen with liquid nitrogen and shipped to
Chenomx Inc. (Canada) on dry ice for NMR analysis.

2.10 Real-time PCR
For quantitative Real-time PCR (qRT-PCR), total RNA was collected using Trizol
Reagents (Invitrogen) and cDNA was synthesized using an iScript cDNA Synthesis Kit
(BioRad). qRT-PCR was performed with an iQ-SYBR Green Supermix (BioRad), an
Applied Biosystems StepOnePlus Realtime PCR system and an iCycler CFX96 RealTime PCR Detection System (BioRad). Actin mRNA and 18S rRNA were used for
normalization.
qRT-PCR primers used to measure mRNA level:
HK2-5’

ATGAGGGGCGGATGTGTATCA

HK2-3’

GGTTCAGTGAGCCCATGTCAA
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GPI-5’

GGTACACAGGCAAGACCATC

GPI-3’

GTTTTGGCAATGTGAGTTCC

PFK1-5’

GGGCGCCAAGGCTATGAACTG

PFK1-3’

GCTCCCACCCACTGCCTGCTC

ALDOA-5’

GGGTGTCATCCTCTTCCATGA

ALDOA-3’

GACCACGCCCTTGTCTACCTT

ALDOB-5’

GGAGGCTTTTATGAAGCGGG

ALDOB-3’

TGAAGAGCGACTGGGTGGAA

TPI-5’

GCACTCAGAGAGAAGGCATGT

TPI-3’

CAATGCAGGCGATTACTCCGA

PGK1-5’

GGGCAAGGATGTTCTGTTCT

PGK1-3’

TCTCCAGCAGGATGACAGAC

PGM1-5’

ACCCACTCCCTTCATACAATC

PGM1-3’

CTCCTCACTGGTCATGGCTTA

ENO1-5’

AAAGCTGGTGCCGTTGAGAAG

ENO1-3’

AGCATGAGAACCGCCATTGAT

PKM2-5’

CGCCCACGTGCCCCCATCATTG
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PKM2-3’

CAGGGGCCTCCAGTCCAGCATTCC

LDHA-5’

TTCAAGGTTTATTGGGGGTTT

LDHA-3’

AGTTCTGCCACCTCTGACG

PDK1-5’

CCGCTCTCCATGAAGCAGTT

PDK1-3’

TTGCCGCAGAAACATAAATGAG

SLC2A1-5’

CCAGCTGCCATTGCCGTT

SLC2A1-3’

GACGTAGGGACCACACAGTTGC

SLC2A2-5’

GCGGCTGCGGGGCTATGATGAT

SLC2A2-3’

CGGGGGCCCTGGGAGAAGAACT

SLC2A4-5’

CTGGGCCTCACAGTGCTAC

SLC2A4-3’

GTCAGGCGCTTCAGACTCTT

TFAM-5’

AAGATTCCAAGAAGCTAAGGGTGA

TFAM 3’

CAGAGTCAGACAGATTTTTCCAGTTT

MT-CO1-5’

TCGCATCTGCTATAGTGGAG

MT-CO1-3’

ATTATTCCGAAGCCTGGTAGG

PPRC1-5’

ACAGGCAGCAAAGCGGTGTG

PPRC1-3’

AGGAATGGCCGTAGAGACGC
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C17-5’

CTTTAACTTGGCTGCTTAGAC

C17-3’

CATAGTTTAGAGGGGACTCC

MT-ND1-5’

CCCATTCGCGTTATTCTT

MT-ND1-3’

AAGTTGATCGTAACGGAAGC

LPL-5’

GGATGGACGGTAAGAGTGATTC

LPL-3’

ATCCAAGGGTAGCAGACAGGT

GLS1-5’

TGGTGGCCTCAGGTGAAAAT

GLS1-3’

CCAAGCTAGGTAACAGACCCTGTTT

2.11 Dual Luciferase Reporter Assay
c-Myc transactivational activity was measured using a Dual-Luciferase Reporter
Assay System from Promega with a Luciferase reporter plasmid containing a TERT
(telomerase reverse transcriptase) promoter. TERT is a c-Myc target gene and its
promoter contains an E-box c-Myc binding site.

2.12 Lentiviral shRNA
14-3-3σ shRNA lentiviral plasmids were purchased from Sigma-Aldrich. 14-3-3σ
shRNA lentiviruses were then produced from 293T cells following the virus production
protocol that is similar to the protocol described in 2.4. Infection efficiency was
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enhanced using 8 µg/ml Polybrene and centrifugation at 2000 rotation per minute for 60
minutes at 32oC. Knockdown efficiency was verified by Western Blot.

2.13 Bioinformatics analysis:
14-3-3σ expression level in human cancers is was analyzed using Oncomine
database and Nexus Expression 3.0 (BioDiscovery). The analysis of transcriptomics
landscapes of human cancer patients was done using data sets GSE5847, GSE2109,
GSE11121, and GSE20194 that were downloaded from Oncomine and Gene
Expression Omnibus databases. These data sets were then analyzed by Gene Set
Enrichment Analysis (GSEA) (Broad Institute), Oncomine, Nexus Expression 3.0
(BioDiscovery), and Gene Spring 12 (Agilent Technologies). The Myc glycolytic target
gene geneset was built by our lab. The Myc target genes geneset was made by
Benporath et al. (GSEA Molecular Signature Database).
(http://www.broadinstitute.org/gsea/msigdb/cards/BENPORATH_MYC_TARGETS_WIT
H_EBOX.html). Pearson correlation analysis was done using Prism and Sigma Plot
programs. Retrospective analysis of patients’ information was done under approved
clinical protocols at MDACC.

2.14 Immunohistochemistry staining
Breast cancer tissue microarrays were provided by the Department of Pathology
at M.D. Anderson Cancer Center (MDACC). The xenograft breast tumor slides were
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constructed by the MDACC Histology Facility Core. Immunohistochemistry Hematoxylin
and Eosin and cleaved Caspase 3 staining was done by the MD Anderson Cancer
Center Tissue Core Lab. Other IHC staining was performed following the IHC staining
protocols provided by the MDACC Department of Pathology. Tissue microarrays and
tumor slides were stained with anti Pyruvate Kinase M2 antibodies (1:300 dilution, Cell
Signaling), anti-Phosphofructose kinase 1 antibodies (1:300 dilution, Novus Biologicals),
anti-14-3-3σ (1:200 dilution, Fitzgerald Industry International), anti-Myc (1:50 dilution,
Epitomics). IHC staining results were analyzed by pathologists of the MDACC
Department of Pathology and quantified using a Dako ChromaVision System ACIS III at
MDACC Department of Molecular and Cellular Oncology.

2.15 Supplemental Information
All experiments involved cancer patients’ samples and information have been
done under approved clinical protocols at M.D. Anderson Cancer Center. All
experiments and procedures involved animals were approved by M.D. Anderson
Cancer Center Institutional Animal Care and Use Committee, which is accredited by the
Association for the Assessment and Accreditation of Laboratory Animal Care
International. All in vitro experiments have been repeated at least 5 times. Statistical
analyses and representative pictures are shown in figures.
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2.16 Biostatistics analysis
All bar graphs and line graphs are represented as mean ± 95% confidence
intervals (CI) unless otherwise stated. All error bars in this thesis also represent 95% CI
unless otherwise stated. The error bars of line graphs from Seahorse Extracellular Flux
Analyzer are standard deviations.

Student t-test has been used to compare the difference between two groups.
One-way analysis of variance (ANOVA) has been employed for comparison if there are
more than two groups unless otherwise stated. * indicates p value less than 0.05. Logrank (Mantel-Cox) test has been used to compare survival times of breast cancer
patients. All experiments have been independently repeated at least 4 times.
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Chapter 3. Results
3.1 High 14-3-3σ expression is associated with good clinical outcomes and
negatively correlated with Myc-induced metabolic genes expression in breast
cancer patients.
By correlating 14-3-3σ protein expression level in breast tumors with clinical data
of breast cancer patients, we found that this tumor suppressor is associated with a
positive impact on these patients’ prognosis. High 14-3-3σ presence in breast tumors is
correlated with a long overall and recurrence-free survival times. 95.7% of breast cancer
patients with high expression of 14-3-3σ in their breast tumors have survived more than
14 years without local or distant metastasis (Figures 12A and 12B). Elevated 14-3-3σ
level was also inversely correlated with tumor grade (Table 2). Thus, these data suggest
a role of 14-3-3σ in suppressing tumorigenesis.

Interestingly, we noticed that high-14-3-3σ breast tumors had very low
18

Fluorodeoxyglucose Positron Emission Tomography Standardized Uptake Values

(18FDG PET SUV) (Figure 13, Table 3). PET Scan with

18

FDG is a powerful nuclear

medicine imaging technique that relies on the high glucose uptake of cancer cells to
detect local and metastatic tumors. Thus, from a metabolic standpoint, this observation
suggested that 14-3-3σ might reduce the ability of tumors to uptake glucose, a vital
nutrient for cancer cells.
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Figure 12
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Figure 12. High 14-3-3σ expression is associated with prolonged overall survival
and metastasis-free survival of breast cancer patients.
(A) High 14-3-3σ expression in tumors is correlated with significantly increased breast
cancer patients’ overall survival. 14-3-3σ protein expression in tumors was quantified
based on immunohistochemistry staining of breast cancer patients’ tumors tissue
microarrays. The average of 14-3-3σ protein expression level of normal breast tissues
was used as a reference to classify cancer patients into high and low 14-3-3σ groups. If
14-3-3σ protein level in tumors of a cancer patient was higher than the average of 14-33σ protein levels in normal breast tissues, that patient was considered as having a “high
14-3-3σ expression”. In contrast, if 14-3-3σ protein level in tumors of a cancer patient
was lower than the average of 14-3-3σ protein levels in normal breast tissues, that
patient was considered as having a “low 14-3-3σ expression”.
(B) Recurrence-free survival of breast cancer patients is considerably improved when
14-3-3σ expression is elevated in tumors. The 14-3-3σ classification standard was the
same as in Figure 12A.

53	
  

Table 1. Demographic and clinical information of breast cancer patient cohort
analyzed in Figure 12

Race

Age at diagnosis

Pathology stage at
diagnosis
Estrogen Receptor status
Progesterone Receptor
status
Human epidermal growth
factor receptor 2 status
Triple Negative Breast
Cancer status

White
Asian
Asian
Pacific
Black
Hispanic
21-40
41-60
61-80
>81
1
2
3
4
Positive
Negative
Positive
Negative
Positive
Negative
Yes
No

High 14-3-3σ
expression group
(N=25)
19 (76%)
1 (4%)

Low 14-3-3σ
expression group
(N=60)
43 (71.6%)
4 (6.7%)

1 (4%)

0 (0%)

1 (4%)
3 (12%)
2 (8%)
15 (60%)
8 (32%)
0 (0%)
12 (48%)
7 (28%)
6 (24%)
0 (0%)
11 (44%)
14 (56%)
14 (56%)
11 (44%)
11 (44%)
14 (56%)
8 (32%)
17 (68%)

9 (15%)
4 (6.7%)
5 (8.33%)
35 (58.33%)
18 (30%)
2 (3.33%)
22 (36.67%)
21 (35%)
17 (28.33%)
0 (0%)
34 (56.67%)
26 (43.33%)
27 (45%)
33 (55%)
46 (76.67%)
14 (23.33%)
12 (20%)
48 (80%)
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Table 2. 14-3-3σ’s expression is inversely correlated with breast tumor grade.
ChiTotal
Tumor Grade

square
Number
Test

1

14-3-3σ
Expression

Total

2

3

Low 7 (70%)

62 (58.5%)

84 (67.7%)

153

p < 0.0001

High 3 (30%)

44 (41.5%)

40 (32.3%)

87

p < 0.0001

10 (100%) 106 (100%)

124 (100%)

240
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Table 2. 14-3-3σ’s expression is inversely correlated with breast tumor grade.
Tumor grade is determined by pathological histology. 14-3-3σ mRNA expression in the
tumors was determined by transcriptomics analysis of breast cancer patients tumors’
fine needle aspirates (microarrays analysis) and normalized to β-actin (ACTB) mRNA
level. The average of 14-3-3σ/β-actin mRNA ratios of normal breast tissues was used
as a reference to classify cancer patients into high and low 14-3-3σ groups. If 14-33σ/β-actin mRNA ratio in tumors of a cancer patient was at least 60% higher than the
average of 14-3-3σ/β-actin mRNA ratios in normal breast tissues, that patient was
considered as having a “high 14-3-3σ expression”. In contrast, if 14-3-3σ/β-actin mRNA
ratio in tumors of a cancer patient was at least 60% lower than the average of 14-33σ/β-actin mRNA ratios in normal breast tissues, that patient was considered as having
a “low 14-3-3σ expression”.
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18

Figure 13. High 14-3-3σ expression is associated with decreased 18FDG uptake in
tumors of breast cancer patients.
(A) Box plot graph implied a negative influence of 14-3-3σ on 18FDG uptake of breast
cancer patients’ tumors. 18FDG PET SUVs of breast cancer patients were measured
and graphed with the expression score of 14-3-3σ, which was determined by
transcriptomics analysis. Data is represented as mean ± 95% confidence intervals (CI).
14-3-3σ mRNA expression in the tumors was determined by transcriptomics analysis of
breast cancer patients tumors’ fine needle aspirates (microarrays analysis) and
normalized to β-actin (ACTB) mRNA level. The average of 14-3-3σ/β-actin mRNA ratios
of normal breast tissues was used as a reference to classify cancer patients into high
and low 14-3-3σ groups. If 14-3-3σ/β-actin mRNA ratio in tumors of a cancer patient
was at least 60% higher than the average of 14-3-3σ/β-actin mRNA ratios in normal
breast tissues, that patient was considered as having a “high 14-3-3σ expression”. In
contrast, if 14-3-3σ/β-actin mRNA ratio in tumors of a cancer patient was at least 60%
lower than the average of 14-3-3σ/β-actin mRNA ratios in normal breast tissues, that
patient was considered as having a “low 14-3-3σ expression”.
(B) Pearson correlation test showed an inverse correlation between 14-3-3σ mRNA
expression and 18FDG uptake.
(C) Representative 18FDG PET Scan pictures indicated the negative impact of 14-3-3σ
on 18FDG uptake in breast cancer patients’ tumors. The 14-3-3σ classification standard
was the same as in Figure 13A.
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Table 3. 14-3-3σ’s expression is inversely correlated with18FDG PET Standardized
Uptake Value in breast cancer patients’ tumors.

PET Standardized Uptake

Total

Value

14-3-3σ
Expression

Chi-squate
Test

Low

High

Low

28.6%

71.4%

100%

p < 0.0001

High

75%

25%

100%

p < 0.0001
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Table 3. 14-3-3σ’s expression is inversely correlated with18FDG PET Standardized
Uptake Value in breast cancer patients’ tumors.
PET Standardized Uptake Value = c(t) / (injected dose t0/body weight).
c(t) is the tissue radioactivity concentration at time t.
Injected dose t0 is the amount of radioactivity injected at the beginning (t=0)
Body weight is the weight of patient in kg.
14-3-3σ mRNA expression in the tumors was determined by transcriptomics analysis of
breast cancer patients tumors’ fine needle aspirates (microarrays analysis) and
normalized to β-actin (ACTB) mRNA level. The 14-3-3σ classification standard was the
same as in Table 2.
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To further understand these correlations, we compared the transcriptomics
landscapes of breast cancer patients having low 14-3-3σ levels (loss of >60% of 14-33σ expression compared to normal breast tissues) with those who exhibited
upregulation of 14-3-3σ (gain >60% of 14-3-3σ expression compared to normal breast
tissues) in cohorts GSE20194, GSE5847, GSE11121 and GSE2109. We noticed that
breast cancer patients with low 14-3-3σ levels have a significant upregulation of Mycinduced target genes, including the genes involved in glycolysis, glutaminolysis and
mitochondrial biogenesis (Figures 14A, 14B, 15A, 15B).

In addition, statistic analyses and Pearson correlation tests showed a negative
correlation between 14-3-3σ expression and the levels of Myc–induced target genes
genes involved in glycolysis, glutaminolysis and mitochondrial biogenesis, for instance,
Glut1

(SLC2A1),

Glut2

(SLC2A2),

Glut4

(SLC2A4),

Hexokinase

2

(HK2),

Phosphofructose kinase 1 (PFK1), Aldolase A (ALDOA), Enolase (ENO1), Pyruvate
Kinase M2 (PKM2), Lactate Dehydrogenase A (LDHA), Glutaminase 1 (GLS1),
glutamine transporter ASCT2 (SLC1A5), TFAM, among others (Figures 15, 16 and 17).
In addition, tissue microarray analysis showed a significant inverse correlation between
14-3-3σ level and Myc protein expression in breast cancer patients’ tumors (Figures
18A and 18B). Thus, these results suggested that 14-3-3σ could suppress cancer
glycolysis, glutaminolysis and mitochondrial biogenesis through the regulation of Myc.
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Figure 14. Myc-induced target genes expression increases in breast tumors that
have low levels of 14-3-3σ.
(A) Heat map from Gene Set Enrichment Analysis (GSEA) indicates an up-regulation of
Myc-induced target genes in breast cancer patients that have a low 14-3-3σ level.
(B) GSEA Enrichment score graph shows the enhancement of Myc target gene
expression in breast cancer patients that have a low 14-3-3σ level. The 14-3-3σ
classification standard was the same as in Table 2.
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Figure 15. Elevation of Myc-induced metabolic target genes expression in breast
tumors that have low levels of 14-3-3σ.
(A) Heat map from Gene Set Enrichment Analysis (GSEA) indicates an up-regulation of
Myc-induced metabolic target genes in breast cancer patients that have a low 14-3-3σ
level.
(B) GSEA Enrichment score graph shows the enhancement of Myc metabolic target
gene expression in breast cancer patients that have a low 14-3-3σ level. The 14-3-3σ
classification standard was the same as in Table 2.
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8

Figure 16. 14-3-3σ expression is inversely correlated with Myc-induced metabolic
target genes levels. Pearson correlation analysis suggests an inverse correlation
between 14-3-3σ presence and the expression of major Myc-induced glycolytic target
genes.
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Figure 17. Transcriptomics analysis indicates a negative correlation between 14-3-3σ
level and the expression of Transcription Factor A, Mitochondrial (TFAM), a Mycinduced gene that is crucial for mitochondrial gene transcription and mitochondrial DNA
replication.
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Figure 18. Negative correlation between 14-3-3σ and Myc protein expression in
breast tumors.
(A) 14-3-3σ expression is inversely correlated with Myc protein level. 14-3-3σ and Myc
protein expression were quantified from immunohistochemistry (IHC) staining of breast
cancer patients tissue microarrays.
(B) Representative IHC pictures show the reverse relationship between 14-3-3σ and
Myc expression in breast cancer patients’ tumors.
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3.2 Loss of 14-3-3σ leads to an increase in glucose consumption and glucose
uptake in cancer cells
To study the impact of 14-3-3σ on cancer glycolysis, we first investigated the
influence of 14-3-3σ on glucose consumption. We measured glucose consumption in
two cell lines that are isogenic except their 14-3-3σ status. Strikingly, we found that 143-3σ null cells exhibit a significant elevation in glucose consumption when compared
with 14-3-3σ wild-type (wt) cells (Figure 19A). 14-3-3σ knockdown leads to a similar
observation (Figure 19B). Interestingly, when 14-3-3σ expression is restored in 14-3-3σ
null cells, glucose consumption falls in a dose-dependent manner (Figure 20A). We also
successfully established two tet-regulated (Tet-On) cell lines from 14-3-3σ null cells:
HCT116 14-3-3σ-/-, MDA-MB-231 (14-3-3σ expression is down-regulated due to
hypermethylation of the promoter region), and again glucose consumption was reduced
in these cells when 14-3-3σ was induced by Doxycycline treatment (Figure 20B). We
then measured glucose uptake in cells using 2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4yl)Amino)-2-Deoxyglucose (2-NBDG), a fluorescent glucose analog that can be
imported into cells and detected by fluorescent microscopy and flow cytometry. The 143-3σ-/- cells had more green signals from 2-NBDG and a faster rate of glucose uptake
(Figures 21A, 21B, 21C). More importantly, re-expression of 14-3-3σ in 14-3-3σ null
cells reverses 2-NBDG incorporation in a dose-dependent manner (Figures 22A, 22B).
We also observed, based on flow cytometry, that 14-3-3σ’s induction led to a significant
decline in the translocation of glucose transporter Glut1 to the cell membrane (Figures
23A, 23B).
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Figure 19. Loss and knockdown of 14-3-3σ leads to an increase in glucose
consumption and uptake.
(A) Enhancement of glucose consumption in 14-3-3σ null cells. Glucose concentration
of the medium was measured by Freestyle glucose meter. Glucose consumption is
normalized to the final cell number and culture time.
(B) 14-3-3σ knockdown results in a significant increase in glucose consumption. 14-33σ expression was knocked down by lentiviral shRNA. Knockdown efficiency was
verified by Western Blot with an anti-14-3-3σ antibody. Luciferase shRNA was used as
a control. Glucose consumption was measured as described in (A).
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Figure 20. Restoration of 14-3-3σ expression in 14-3-3σ-deficient cancer cells
leads to decreased glucose consumption.
(A) 14-3-3σ reduces glucose consumption in a dose dependent manner. HCT116 14-33σ-/- cells were transfected with increasing amounts of pCMV5-Flag-14-3-3σ plasmid,
and glucose consumption was measured.
(B) Induced expression of 14-3-3σ significantly diminishes glucose consumption.
Indicated cells were infected with retroviruses carrying a Tet On Flag-14-3-3σ system as
described in Extended Experimental Procedures. Flag-14-3-3σ expression was induced
(+) for 48 hours using 5 ng/ml Doxycycline. Non-induced (-) cells are used as the
corresponding control. Flag-14-3-3σ induction was verified by Western Blot. Glucose
consumption was measured.
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Figure 21. Loss of 14-3-3σ increases glucose uptake.
(A) Microscopic pictures demonstrate that loss of 14-3-3σ results in a remarkable
enhancement of glucose uptake. Cells were incubated in a DMEM glucose-free medium
containing 120 µM of 2-NBDG, for the indicated times. 2-NBDG signals were observed
using fluorescent microscopy.
(B) Flow cytometry analysis shows a significant increase in 2-NBDG signals in HCT116
14-3-3σ-/- cells when compared with HCT116 wt cells.
(C) Bar graph and statistic analysis of Figure 21B. Data is represented as mean ± 95%
confidence interval (CI)
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Figure 22. 14-3-3σ expression decreases glucose uptake in HCT116 14-3-3σ-/cancer cells.
(A) 14-3-3σ transfection decreases 2-NBDG uptake in a dose-dependent manner.
Indicated cells were transfected with indicated amounts of pCMV5-Flag-14-3-3σ. 2NBDG signal was measured using a flow cytometer as in Figure 21.
(B) Representative pictures from a fluorescent microscope for the experiment in Figure
22A.
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Figure 23. 14-3-3σ decreases the expression of glucose transporter Glut1 on
cellular membrane.
(A) Doxycycline-induced expression of Flag-14-3-3σ results in a sharp decline of Glut1
expression on cellular membrane surface. Flag-14-3-3σ was induced by Doxycycline in
MDA-MB-231 as previously described. Cells were stained with specific anti-Glut1
antibodies conjugated with APC fluorophore and analyzed by flow cytometry.
(B) Bar graph and statistical analyses of Figure 23A were done using GraphPad Prism
v5.0d and Sigma Plot 12.0. Data is represented as mean ± 95% CI.

82	
  

3.3 14-3-3σ suppresses lactate production and decreases ATP concentration in
cancer cells
Lactate is a final product of aerobic glycolysis. Therefore, we hypothesize that
since 14-3-3σ null cells have increased glucose consumption and uptake, they may
produce more lactate. As we expected, 14-3-3σ null cells produced significantly more
lactate when compared with 14-3-3σ wt cells (Figures 24A and 24C). Accordingly, 14-33σ knockdown led to higher lactate production (Figure 24B). Significantly, re-expressing
14-3-3σ in 14-3-3σ null cells reduced lactate generation in a dose-dependent manner
(Figure 25A). We also found that Doxycycline-induced restoration of 14-3-3σ expression
in HCT116 14-3-3σ-/- and MDA-MB-231 cells led to the reduction of lactate
accumulation in the culture medium (Figure 25B).
Since the production of lactate acidifies the extracellular environment, we next
measured the extracellular acidification rate (ECAR) using a Seahorse Extracellular
Flux Analyzer XF24 (Seahorse Bioscience). We found that HCT116 14-3-3σ-/- cells had
a higher ECAR when compared with HCT116 wt cells (Figure 26A). The impact of 14-33σ was even more obvious when the cells were treated with oligomycin, a drug that
inhibits mitochondrial ATP synthesis and drives the cells to utilize more glycolytic
pathway (Figure 26A). ECAR also increased when 14-3-3σ expression was knocked
down in MCF10A and T47D breast cancer cells (Figure 26B). We also analyzed ECAR
in tet-regulated HCT116 14-3-3σ-/-, MDA-MB-231 and MDA-MB-435 cells. Again, ECAR
was reduced in these cells when 14-3-3σ expression was induced by the Doxycycline
treatment (Figures 27A, 27B, 27C). In hypoxic condition, restoring 14-3-3σ expression
also suppressed lactate production of HCT116 14-3-3σ-/- and MDA-MB-231 cells
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(Figures 28A, 28B).
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Figure 24. Loss of 14-3-3σ increases lactate production.
(A) Loss of 14-3-3σ increases lactate production. Lactate concentration was measured
in the medium of the indicated cultured cells using the lactate analyzer Accutrend
(Roche) and normalized to the final cell number and culture time.
(B) 14-3-3σ knockdown increases lactate production. 14-3-3σ expression was knocked
down using lentiviral shRNA as mentioned above. Lactate production assay was
measured as in (A).
(C) Loss of 14-3-3σ results in a significant increase in the concentrations of lactate and
other important metabolites. Metabolites are extracted from HCT116 wt, 14-3-3σ-/- cells
and HCT116 14-3-3σ-/- cells that are infected with Adenoviruses carrying β
galactosidase or 14-3-3σ using freezing/thawing method. Metabolite concentrations are
then measured using Nuclear Magnetic Resonance by Chenomx (Alberta, Canada).
Metabolite names that are printed in orange color are related to glycolysis,
glutaminolysis, phospholipid metabolism and the Tricarboxylic Acid cycle.
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Figure 25. 14-3-3σ expression decreases lactate production of cancer cells.
(A) 14-3-3σ transfection reduces lactate production in a dose-dependent manner.
Indicated cells were transfected with increasing amounts of pCMV5-Flag-14-3-3σ
plasmid. Lactate production was measured as previously described.
(B) Induced expression of 14-3-3σ results in a sharp decline of lactate production. Flag14-3-3σ was induced by Doxycycline in the indicated cells. Lactate production was
measured as previously described.
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Figure 26. Loss and knockdown of 14-3-3σ elevates Extracellular Acidification
Rate (ECAR).
(A) Loss of 14-3-3σ increases ECAR. Indicated cells were plated in a Seahorse
Bioscience microplate for ECAR measurement using a Seahorse Extracellular Flux
Analyzer XF24.
(B) Knockdown of 14-3-3σ in MCF10A and T47D breast cancer cells significant
increases ECAR.
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Figure 27. 14-3-3σ decreases lactate production.
(A) Induced expression of Flag-14-3-3σ in HCT116 14-3-3σ-/- cells diminishes ECAR.
Flag-14-3-3σ is induced by Doxycycline as described above.
(B) Flag-14-3-3σ expression decreases ECAR in MDA-MB-231 cells.
(C) 48-hour inducible expression of Flag-14-3-3σ in MDA-MB-435 breast cancer cells
remarkably reduces ECAR.
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Figure 28. 14-3-3σ expression decreases lactate production in hypoxia.
Inducible expression of Flag-14-3-3σ in MDA-MB-231 (A) and HCT116 14-3-3σ-/- (B)
cancer cells remarkably decreases ECAR in hypoxic condition. MDA-MB-231 and
HCT116 14-3-3σ-/- cells that carry a Tet On 14-3-3σ system are cultured in hypoxic
condition (1% oxygen) and treated with 5 ng/ml Doxycycline for 48 hours to induce Flag14-3-3σ expression.
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Since ATP production is tightly linked to metabolic activities, we also evaluated
the impact of 14-3-3σ on ATP in cancer cells. Significantly, we found that HCT116 14-33σ null cell have a higher ATP concentration when compared with 14-3-3σ wt cells
(Figure 29A). Accordingly, we found that HCT116 14-3-3σ knockdown cells also had
significantly higher levels of ATP when compared with 14-3-3σ control cells (Figure
29B). Another line of evidence also showed that Doxycycline-induced Flag-14-3-3σ
expression in HCT116 14-3-3σ-/- cells and MDA-MB-231 cells reduced ATP
concentrations (Figure 29C). Our data suggests that 14-3-3σ loss not only enhances
glycolysis but also potentiates cells to engage in a metabolic program that produces
more ATP.
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Figure 29. The negative impact of 14-3-3σ on ATP level in cancer cells
(A) Loss of 14-3-3σ increases ATP concentration.
(B) 14-3-3σ knockdown results in a significant rise of ATP concentration in HCT116
cells.
(C) Induced expression of 14-3-3σ causes a significant decline of ATP level. Flag-14-33σ was induced by Doxycycline in indicated cells as described above. All data is
represented as mean ± 95% CI.
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3.4 14-3-3σ promotes Myc ubiquitination, accelerates Myc turnover rate,
suppresses its transcriptional activity, and decreases Myc-induced glycolytic
target genes expression.
Since Myc has been identified as a major driver of cancer glycolysis and we
observed a negative correlation between 14-3-3σ and Myc protein levels in breast
cancer patients’ tumors, we decided to further examine the impact of 14-3-3σ on Myc.
Interestingly, we found that Doxycycline-induced Flag-14-3-3σ expression in HCT116
14-3-3σ-/- and MDA-MB-231 increased Myc poly-ubiquitination in these cells (Figure
30A). In addition, the induction of 14-3-3σ expression in HCT116 p53-/- cells and H1299
cells (both of which are p53 null cells) also enhanced Myc poly-ubiquitination, which
suggests that 14-3-3σ’s impact on Myc ubiquitination is p53-independent (Figure 30B).
Furthermore, the protein turnover rate of Myc increased in HCT116 14-3-3σ-/- and MDAMB-231 cells when Flag-14-3-3σ expression was induced by Doxycycline compared
with the non-induced cells (Figures 31A, 31B, 31C).
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Figure 30. 14-3-3σ promotes c-Myc poly-ubiquitination.
(A) Doxycycline-induced Flag-14-3-3σ increases Myc ubiquitination. HCT116 14-3-3σ-/TetR 14-3-3σ and MDA-MB-231 TetR 14-3-3σ cells are treated with Doxycycline to
induce Flag-14-3-3σ expression (+). Non-induced cells were used as a control (-). Cell
lysates were immunoprecipitated with anti-Myc antibodies and immunoblotted with antiubiquitin antibodies.
(B) 14-3-3σ enhances c-Myc ubiquitination in p53-deficient cancer cells. H1299 TetR
14-3-3σ and HCT116 p53-/- TetR 14-3-3σ cells are grown in the presence of 5 ng/ml
Doxycycline for 48 hours to induce Flag-14-3-3σ expression. Non-induced cells are
used as control for comparison. All cells are then treated with MG132, a potent
proteasome inhibitor, for 5 hours. Cell lysates are collected and immunoprecipitated
with anti-Myc antibodies (Sigma Aldrich) and immunoblotted with anti-ubiquitin
antibodies (Santa Cruz).
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Figure 31. 14-3-3σ increases Myc turnover rate.
(A) Flag-14-3-3σ was induced by Doxycycline in HCT116 14-3-3σ-/- TetR 14-3-3σ cells
as described above. Cells were treated with 200 µg/ml Cycloheximide (Chx) for the
indicated times. Cell lysates are immunoblotted with indicated antibodies.
(B) Inducible expression of Flag-14-3-3σ accelerates Myc degradation in HCT116 14-33σ-/- cells. Line graph is built based on Western Blot data of Figure 32A.
(C) 14-3-3σ promotes Myc degradation in MDA-MB-231 TetR 14-3-3σ cells. This
experiments was done in a similar way as Figure 31A.
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To correlate the decrease in Myc stability with the regulation of Myc
transcriptional activity, we did a luciferase reporter gene assay. We found that Flag-143-3σ induction by Doxycycline treatment diminished Myc transcriptional activity in both
HCT116 14-3-3σ-/- and MDA-MB-231 cells (Figure 32). Significantly, our quantitative
Real time PCR (qRT-PCR) data show that loss and knockdown of 14-3-3σ enhanced
the expression of Myc glycolytic target genes, e.g., HK2, GPI, PFK1, ALDOA, ENO1,
TPI1, PGK1, PKM2, LDHA, among others, both in normoxic and hypoxic conditions
(Figures 33 & 34). Conversely, Flag-14-3-3σ induction by Doxycycline treatment
resulted in strong suppression of Myc glycolytic target genes both in normoxia and
hypoxia (Figure 35).
To further confirm the gene expression data, we performed Western Blot to
determine the protein expression of glycolytic enzymes in these cells. We found that the
protein levels of Myc glycolytic target genes were consistent with the mRNA expression
pattern (Figures 36A, 36B, 37). It is important to point out that Phosphoglucose Mutase
1 (PGM1), the only glycolytic enzyme that is not a transcriptional target of Myc, was not
affected by the loss, knockdown and re-expression of 14-3-3σ (Figures 33A, 33B, 35A,
36A, 36B, 37). This indicates that 14-3-3σ’s negative impact on glycolytic gene
expression is selective for Myc targets. Together, these data demonstrate that 14-3-3σ
reduces the expression of Myc target genes involved in glycolysis by promoting Myc
degradation and suppressing Myc transcriptional activity.
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Figure 32. 14-3-3σ decreases Myc transactivational activity. Indicated cells were
transfected with Tert luciferase reporter plasmid containing a c-Myc response element
(Ebox). Relative Luciferase Activity was measured.
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Figure 33. Loss and knockdown of 14-3-3σ increases the expression of Mycinduced glycolytic target genes.
(A) Loss of 14-3-3σ leads to mRNA upregulation of Myc-targeted glycolytic genes. Total
RNA is extracted from HCT116 wt and 14-3-3σ-/- cells for qRT-PCR using specific
primers for the indicated genes.
(B) Knockdown of 14-3-3σ elevates Myc-targeted glycolytic genes mRNA levels. 14-33σ expression was knocked down using lentiviral shRNAs. Luciferase shRNA-infected
cells were used as a control.
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Figure 34. Loss and knockdown of 14-3-3σ increase the expression of Mycinduced glycolytic target genes in hypoxic condition.
(A) Loss of 14-3-3σ increases Myc-induced glycolytic target genes expression in
hypoxia. HCT116 WT and HCT116 14-3-3σ-/- cells are cultured in hypoxia (1% oxygen)
for 48 hours. Total RNA is collected, converted to cDNA and used for qRT-PCR.
(B) Knockdown of 14-3-3σ elevates Myc-induced glycolytic target genes expression in
hypoxia. 14-3-3σ expression is knockdown in HCT116 WT using lentiviral shRNA.
Luciferase shRNA is used as a control. All cells are cultured in hypoxia (1% oxygen) for
48 hours. Total RNA is collected, converted to cDNA and used for qRT-PCR.
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Figure 35. 14-3-3σ down-regulates Myc-induced glycolytic target genes
expression both in normoxic and hypoxic conditions.
(A) Doxycycline-induced Flag-14-3-3σ decreases mRNA expression of Myc-induced
glycolytic target genes in normoxic condition. Flag-14-3-3σ was induced by Doxycycline
as described above. qRT-PCR is performed using specific primers for the indicated
genes.
(B) Inducible expression of Flag-14-3-3σ decreases Myc-induced glycolytic target genes
level in MDA-MB-231 cells in hypoxic condition. MDA-MB-231 cells that carries a Tet
On 14-3-3σ system are cultured in hypoxia (1% oxygen) and treated with 5 ng/ml
Doxycycline for 48 hours. Non-induced cells are used as a control. Total RNA is
collected, converted to cDNA and used for qRT-PCR.
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Figure 36. Loss and knockdown of 14-3-3σ increase Myc-induced glycolytic target
genes expression at protein level.
(A) Loss of 14-3-3σ increases the protein level of Myc-induced glycolytic target genes.
Indicated cell lysates were immunoblotted with indicated antibodies.
(B) Knockdown of 14-3-3σ upregulates protein level of Myc-induced glycolytic target
genes. Indicated cell lysates from cells infected with Luciferase shRNA or 14-3-3σ
shRNA #419 and #483 were immunoblotted with indicated antibodies.
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Figure 37. Doxycycline-induced Flag-14-3-3σ decreases protein level of Myctargeted glycolytic genes. Flag-14-3-3σ was induced by Doxycycline as described
above. Cell lysates were immunoblotted with indicated antibodies.
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3.5 14-3-3σ regulates glutaminolysis and mitochondrial biogenesis by controlling
Myc transcriptional activity

Since Myc induces glutaminolysis and mitochondrial biogenesis, both of which
enhance cellular oxygen usage, we employed the Seahorse Bioscience Extracellular
Flux Analyzer XF24 (Wu et al., 2007) to measure the influence of 14-3-3σ on oxygen
consumption rate (OCR). We found that loss of 14-3-3σ increased oxygen consumption
in HCT116 cells (Figure 38A). Similar results were found using another oxygen
consumption measurement method (Figure 38B). Likewise, knockdown of 14-3-3σ
elevated OCR. On the contrary, we observed that inducing Flag-14-3-3σ expression in
HCT116 14-3-3σ-/-, MDA-MB-231 and MDA-MB-435 cells led to a reduction in OCR in
comparison to the control cells (Figure 39).

In the OCR assay, oligomycin, a mitochondrial ATP synthase inhibitor, is added
to measure the respiratory capacity used for ATP synthesis. Then, oxygen consumption
can be stimulated again when oxidative phosphorylation is uncoupled by addition of
FCCP (Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone), which destroys the
mitochondrial membrane potential and causes a short-circuit in the respiratory chain.
Thus, using FCCP allows us to determine the reserved maximal respiratory capacity of
mitochondria. Following this, oxygen consumption can be completely stopped when
rotenone (inhibitor of mitochondrial complex I) and antimycin A (inhibitor of
mitochondrial complex III) are injected to stop mitochondrial electron transport. Hence,
rotenone and antimycin A usage enables us to quantify the non-mitochondrial
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respiration.

Our measurements show that induced 14-3-3σ re-expression in HCT116 14-33σ-/-, MDA-MB-231 and MDA-MB-435 cells resulted in a remarkable reduction of basal
oxygen consumption level, respiration-mediated ATP production, maximal respiration
capacity as well as non-mitochondrial respiration (Figure 39). Reversely, loss and
knockdown of 14-3-3σ expression increased all recently described respiratory
parameters (Figure 38). Thus, 14-3-3σ has a strong negative impact on oxygen
consumption in cancer cells.
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Figure 38. 14-3-3σ suppresses oxygen consumption.
(A) Loss of 14-3-3σ enhances oxygen consumption. Oxygen Consumption Rate
(OCR) of HCT116 wt and 14-3-3σ-/- cells was measured using a Seahorse
Bioscience Extracellular Flux Analyzer XF96 as described in Chapter 2 (Materials
and Methods).
(B) Loss of 14-3-3σ increases oxygen consumption. HCT116 wt and HCT116 14-33σ--/- cells are cultured in BD Biosciences Oxygen Biosensor System microplates
that have been previously coated with fibronectin to enhance cell attachment. The
bottom of each well is embedded with an oxygen sensitive fluorescent compound
(tris 1,7-diphenyl-1,10 phenanthroline ruthenium (II) chloride) that emits fluorescence
when oxygen is consumed. To prevent oxygen exchange with environment, prior to
measurement, mineral oil is applied to the surface of each well. Fluorescent signals,
the indicators of oxygen consumption, are quantified by a Biotek luminometer that
excites the oxygen sensitive fluorescent compound at 485 nm wavelength and
capture the emitted 630 nm fluorescence.
(C) Knockdown of 14-3-3σ expression increases OCR in MCF10A cells. 14-3-3σ
expression is knockdown in MCF10A cells using lentiviral shRNA. Luciferase shRNA
is used as a control.
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Figure 39. Induction of Flag-14-3-3σ decreases Oxygen Consumption Rate (OCR).
Flag-14-3-3σ expression is induced in HCT116 14-3-3σ-/- TetR 14-3-3σ (A), MDA-MB231 TetR 14-3-3σ (B) and MDA-MB-435 TetR 14-3-3σ (C) cancer cells with 5 ng/ml
Doxycycline for 48 hours. Non-induced cells are used as a control. OCR is measured
using Seahorse Extracellular Flux Analyzer XF96 as previously described.
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Myc is known to promote glutaminolysis by elevating the gene expression of
glutamine transporters (SN2 and ASCT2) and Glutaminase 1 (GLS1) (Dang, 2010a;
Gao et al., 2009; Wise et al., 2008; Yeung et al., 2008). Glutamine is transported into
cells by transporters and is converted to α- ketoglutarate (α-KG) through the anaplerotic
metabolism of glutamate to enter TCA cycle. Glutaminase is involved in the conversion
of glutamine to glutamate. We showed that induced Flag-14-3-3σ expression downregulates SN2, ASCT2, and GLS1 (Figures 40A, 40B). Also, induced Flag-14-3-3σ
expression leads to a reduction in ammonia production (Figure 41A), an important byproduct of glutaminolysis (Eng et al., 2010), indicating the suppression of cancer
glutaminolysis by 14-3-3σ. Additionally, glutamate concentration increased upon 14-33σ loss and decreased upon 14-3-3σ re-expression (Figure 24C). Also, 14-3-3σ
induction by doxycycline treatment suppressed GLS1 protein level in three different cell
lines (Figure 41B), whereas loss and knockdown of 14-3-3σ led to increased GLS1
protein expression (Figure 41C). Thus, these findings show that 14-3-3σ has a negative
impact on glutaminolysis in cancer.
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Figure 40. 14-3-3σ expression down-regulates Myc target genes involved in
glutaminolysis.
(A) HCT116 14-3-3σ-/- TetR 14-3-3σ cells are grown in the presence of 5 ng/ml
Doxycycline for 48 hours to induce Flag-14-3-3σ expression. Non-induced cells are
used as a control. Total RNA is then extracted and converted to cDNA for qRT-PCR
reactions with specific primers for GLS1, SN2 and ASCT2, the three Myc target genes
involved in glutaminolysis.
(B) Doxycycline-induced Flag-14-3-3σ decreases GLS1, SN2 and ASCT2 mRNA
expression. Flag-14-3-3σ was induced by Doxycycline in MDA-MB-231 TetR 14-3-3σ
cells as described above. qRT-PCR was performed using specific primers for the
indicated genes.
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Figure 41. 14-3-3σ decreases ammonia production (an important by-product of
glutaminolysis) and down-regulates Glutaminase 1 protein expression.
(A) Doxycycline-induced Flag-14-3-3σ decreases ammonia production. Flag-14-3-3σ
was induced by Doxycycline in cells as described above. Cell lysates are used for
ammonia production measurement.
(B) Doxycycline-induced 14-3-3σ reduces Glutaminase 1 (GLS1) protein expression.
Flag-14-3-3σ was induced by Doxycycline in cells as described above. Cell lysates were
immunoblotted with anti-GLS1 antibodies.
(C) Loss and knockdown of 14-3-3σ increase GLS1 protein level. Cell lysates of
HCT116 wt, HCT116 14-3-3σ-/-, HCT116 Luciferase shRNA, HCT116 14-3-3σ shRNA
#419 and #483 cells are collected and immunoblotted with anti-GLS1 antibodies.
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Myc is a strong inducer of mitochondrial biogenesis by upregulating multiple
genes that are mitochondrial components and increasing mitochondrial DNA replication
(Li et al., 2005). As 14-3-3σ down-regulates Myc, we hypothesize that 14-3-3σ will also
have a suppressive impact on Myc-mediated mitochondrial biogenesis. Therefore, we
stained the cells with 10-Nonyl Acridine Orange (NAO), which associates with
mitochondrial Cardiolipin and allows us to measure mitochondrial mass (Li et al., 2005).
We found that loss of 14-3-3σ leads to an increase in mitochondrial mass (Figures 42A,
42B). Also, using MitoTracker Green FM, a dye that binds to the thiol group of
mitochondria and only stains functional mitochondria, we observed that induced Flag14-3-3σ expression has a negative impact on mitochondrial mass in HCT116 14-3-3σ-/-,
MDA-MB-231, HCT116 p53-/-, and H1299 cancer cells (Figures 43A, 43B).
Moreover, induced Flag14-3-3σ expression in cancer cells leads to the reduction
of gene expression of mitochondrial cytochrome c oxidase I (MT-CO1), NADH
dehydrogenase 1 (MT-ND1) and TFAM (Li et al., 2005) (Figure 44), which is a Myctransactivated target gene. TFAM is very important for mitochondrial gene transcription
and mitochondrial DNA (mtDNA) replication (Li et al., 2005). Therefore, we then
measured the ratio of mtDNA to nuclear DNA using qRT-PCR (Bogacka et al., 2005; Li
et al., 2005). Both the ratio of MT-CO1 to nuclear peroxisome proliferator-activated
receptor gamma (PPRC1) and the ratio of MT-ND1 to nuclear lipoprotein lipase (LPL)
were reduced when Flag-14-3-3σ was induced, which suggests a reduction of mtDNA
copy number due to Flag-14-3-3σ induction (Figure 44). Thus, by promoting Myc
degradation, 14-3-3σ decreases the expression of many Myc target genes that are
important for glutaminolysis, and mitochondrial biogenesis.
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Figure 42. Loss of 14-3-3σ significantly increases mitochondrial mass. Indicated
cells were stained with 10-Nonyl Acridine Orange (10-NAO). The 10-NAO signal was
quantified by flow cytometry (A). The 10-NAO signal intensity is presented as a bar
graph (B).
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Figure 43. 14-3-3σ expression decreases mitochondrial mass.
(A) Doxycycline-induced Flag-14-3-3σ leads to a significant decline in mitochondrial
mass in multiple cancer cell lines. Cell were stained with MitoTracker Green FM and
then analyzed by flow cytometry.
(B) Bar graphs of Figure 43A showing the negative impact of 14-3-3σ on mitochondrial
mass of cancer cells. All data is represented as mean ± 95% CI.
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Figure 44. Flag-14-3-3σ induction decreases mitochondrial gene expression and
biogenesis. Flag-14-3-3σ was induced by Doxycycline in HCT116 14-3-3σ-/- TetR 14-33σ and MDA-MB-231 TetR 14-3-3σ cells as described above. qRT-PCR was performed
using specific primers for the indicated genes. The expression ratios of MT-CO1/
PPRC1 and MT-ND1/LPL were also quantitated using qRT-PCR. All data is represented
as mean ± 95% CI.
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3.6 The regulation of cancer metabolism by 14-3-3σ is via targeting Myc and does
not require p53 impact.

To study whether Myc is a critical mediator in cancer metabolism suppression by
14-3-3σ, we used lentiviral shRNA to knockdown Myc (Figure 45). We observed that in
the presence of Myc knockdown, neither ECAR nor OCR decreased any further when
14-3-3σ was induced, suggesting that Myc down-regulation is a major mechanism for
14-3-3σ-mediated inhibition of cancer cell metabolism (Figure 45).

On the other hand, as 14-3-3σ is a p53-induced target gene that exerts a positive
feedback to stabilize p53 (Yang et al., 2003; Yang et al., 2007) and p53 is also a major
metabolic regulator (Bensaad et al., 2006; Ide et al., 2009; Matoba et al., 2006), it is
important to determine whether 14-3-3σ-mediated regulation of cancer energy
metabolism depends on p53 impact. Interestingly, ECAR and OCR were also reduced
upon Flag-14-3-3σ induction in these p53 null cells (Figure 46). Furthermore, induced
expression of Flag-14-3-3σ in p53 null cell lines (H1299 and HCT116 p53-/-) still
diminished glucose consumption, ATP level and Myc transcriptional activity (Figure 47A,
47B, 47C).

Additionally, we found that induced expression of 14-3-3σ in H1299 cells led to
the down-regulation of Myc, HK2, PFK1 and PKM2 (Figure 47D). Furthermore,
mitochondrial mass decreased when 14-3-3σ was re-expressed in MDA-MB-231 (p53
mutated), HCT116 p53-/- and H1299 cancer cells (Figures 43A, 43B, 44). The negative
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influence of 14-3-3σ on Myc stability, Myc transactivational ability, and Myc-induced
glycolytic target gene expression was also observed in p53 mutated cell line MDA-MB231 (Figures 30A, 32, 35A, 37). Thus, these data suggest that 14-3-3σ controls cancer
energy metabolism through the regulation of Myc in a manner that doesn’t require p53
impact.
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Figure 45. c-Myc knockdown compromises 14-3-3σ-mediated down-regulation of
ECAR and OCR. MDA-MB-231 TetR 14-3-3σ cells were infected with lentiviruses
carrying c-Myc shRNA. Cell lysates were immunoblotted with anti-Myc antibodies. Cells
infected with Luciferase shRNA, Myc shRNA #1614 and Myc shRNA #1657 were then
treated with Doxycycline to induce Flag-14-3-3σ expression (+). Non-induced cells were
used as a control (-). ECAR and OCR were measured as previously described.
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Figure 46. Lack of p53 does not hinder 14-3-3σ’s ability to suppress ECAR and
OCR. H1299 TetR 14-3-3σ and HCT116 p53-/- TetR 14-3-3σ cells were treated with
Doxycycline to induce Flag-14-3-3σ expression (+). Non-induced cells were used as a
control (-). ECAR and OCR were measured. All data is represented as mean ± standard
deviation.
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Figure 47. Lack of p53 doesn’t prevent the negative impact of 14-3-3σ on cancer
metabolism and Myc-induced glycolytic target gene expression.
(A) Induction of Flag-14-3-3σ decreases glucose consumption in H1299 cancer cells.
H1299 is a lung cancer cell line that lost p53 expression. H1299 cells that carry a Tet
On 14-3-3σ system are cultured with 5 ng/ml Doxycycline to induce Flag-14-3-3σ
expression for 48 hours. Glucose consumption is measured as previously described.
(B) Induction of Flag-14-3-3σ diminishes ATP level in HCT116 p53-/- cancer cells.
HCT116 p53-/- cancer cells lost p53 expression due to homologous recombination.
HCT116 p53-/- cells that carry a Tet On 14-3-3σ system are cultured with 5 ng/ml
Doxycycline to induce Flag-14-3-3σ expression for 48 hours. ATP concentration is
measured as previously described.
(C) 14-3-3σ reduces Myc transactivational activity in p53 null cells. H1299 TetR 14-3-3σ
and HCT116 p53-/- TetR 14-3-3σ cells are transfected with Luciferase reporter plasmid
that contains Myc binding sites (Ebox), and Renilla Luciferase plasmid. 24 hours after
transfection, Flag-14-3-3σ expression is then induced with 5 ng/ml Doxycycline for 48
hours. Non-induced cells are used as control. Cell lysates are then collected and used
in Dual Luciferase Assay (Promega).
(D) 14-3-3σ diminishes the expression of Myc and Myc glycolytic target genes in p53deficient H1299 cells. H1299 TetR 14-3-3σ cells are cultured in the presence of 5 ng/ml
Doxycycline for 48 hours to induce Flag-14-3-3σ expression. Non-induced cells are
used as control. Cell lysates are collected and immunoblotted with the indicated
antibodies.
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3.7 14-3-3σ suppresses cancer glycolysis, glutaminolysis and mitochondrial
biogenesis in vivo

We have found that 14-3-3σ functioned as an important regulator of cancer
metabolism in vitro. To validate the impact of 14-3-3σ on cancer bioenergetics in vivo,
we established an orthotopic xenograft mouse model using MDA-MB-231 breast cancer
cells that carry an inducible tet-On 14-3-3σ expression system (please see Materials
and Methods #2.5, page 29). The experimental group received Doxycycline in their
drinking water for 2 weeks to induce 14-3-3σ expression while the control group was not
treated with Doxycycline. We then used

18

FDG microPET scan to assess the impact of

14-3-3σ on glucose uptake in vivo.

Our data showed that Flag-14-3-3σ induction caused a 50% reduction in glucose
uptake of the xenograft tumors (Figure 48A). To further confirm that 14-3-3σ expression
suppresses cancer glycolysis, we extracted and analyzed the xenograft tumors using
qRT-PCR and Western Blot. We found that induction of Flag-14-3-3σ by Doxycycline
led to the suppression of all Myc-induced glycolytic target genes (Figures 48B, 49A).
Again, expression of PGM1, (a glycolytic gene that is not controlled by Myc), was not
suppressed by the induction of 14-3-3σ, indicating the selective impact of 14-3-3σ on
Myc-induced glycolytic target genes (Figures 48B, 49A).

Immunohistochemistry studies on cancer samples from this mouse model also
indicated that the expression of key glycolytic enzymes such as PKM2 and PFK1 was
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suppressed during tumorigenesis by Flag-14-3-3σ induction (Figure 49B). Flag-14-3-3σ
induction also resulted in higher cleaved Caspase 3 level, suggesting an increase in
apoptosis (Figure 49B). More importantly, induction of Flag-14-3-3σ in the xenograft
tumors additionally led to the reduced expression of Myc-regulated genes involved in
glutaminolysis, e.g, GLS1, SN2 and ASCT2 (Figures 49A and 50A). Similarly, induction
of Flag-14-3-3σ in tumors diminishes the expression of MT-CO1, MT-ND1, and MTCO1/PPRC1 ratio, which reflects a reduction of the mtDNA copy number due to 14-3-3σ
(Figure 50B).

We also used this Doxycycline-induced mouse cancer model for Magnetic
Resonance Spectroscopy Imaging with a hyperpolarized

13

C pyruvate tracer (Figure

51). We found that after 2 weeks of Flag-14-3-3σ induction (day 14), 13C pyruvate-to-13C
lactate flux markedly diminished in MDA-MB-231 xenograft tumors compared with noninduced control tumors at day 0 (Figure 51A). A snapshot of Magnetic Resonance
spectra additionally indicates that 14-3-3σ hinders the
conversion (Figure 51B). The rate constant of

13

13

C pyruvate-to-13C lactate

C pyruvate-to-13C lactate reaction (kPL)

in MDA-MB-231 xenograft tumors was calculated (Harris et al., 2009) and shown to be
reduced by 45% after induction of Flag-14-3-3σ when compared with the non-induced
group (Figure 51C).
In summary, our data indicates that the role of 14-3-3σ in suppressing Mycpromoted glycolysis, glutaminolysis, and mitochondrial biogenesis can be recapitulated
in vivo.
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Figure 48. 14-3-3σ suppresses cancer glycolysis in vivo.
(A) Doxycycline-induced Flag-14-3-3σ expression results in a remarkable decrease in
18
FDG uptake in MDA-MB-231 xenograft breast tumors. MDA-MB-231 TetR 14-3-3σ
breast cancer cells were injected into the mammary fat pad of a female nude mouse.
Tumor growth was monitored for 4 weeks. After that, mice were divided into 2 groups.
The experimental group received 200 µg/ml doxycycline in their drinking water for 2
weeks to induce Flag-14-3-3σ expression (+). The control group only received normal
drinking water (-). All mice were then imaged with Magnetic Resonance Imaging and
microPET Scan. The white arrows indicate tumor location. The relative 18FDG uptake
ratio was calculated and is presented as a bar graph.
(B) Down-regulation of Myc-targeted glycolytic gene expression in xenograft breast
tumors with Flag-14-3-3σ induction. After microPET and MRI imaging, tumors were
extracted from the mice. Total RNA was collected for qRT-PCR using specific primers
for the indicated genes.
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Figure 49. The negative impact of 14-3-3σ on Myc-targeted glycolytic genes
expression in vivo.
(A) Flag-14-3-3σ induction down-regulates protein level of Myc-targeted glycolytic
genes in xenograft tumors. Cell lysates from MDA-MB-231 TetR 14-3-3σ xenograft
tumors were immunoblotted with the indicated antibodies.
(B) Flag-14-3-3σ induction reduces PKM2 and PFK1 expression in xenograft tumors.
Immunohistochemistry (IHC) staining of indicated xenograft tumors was performed with
the indicated antibodies. Representative pictures are shown. IHC signals on all slides
were then quantified using a Dako ChromaVision ACIS III system and are displayed in
bar graphs.
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Figure 50. 14-3-3σ decreases glutaminolysis and mitochondrial biogenesis in
vivo.
(A) Flag-14-3-3σ induction reduces expression of genes involved in glutaminolysis in
xenograft breast tumors. Indicated mRNA levels were measured by qRT-PCR as
previously described.
(B) Reduction of mitochondrial biogenesis in xenograft breast tumor upon Flag-14-3-3σ
induction. Mitochondrial gene expression and TFAM level was quantified by qRT-PCR
using the cDNA from xenograft tumor RNA. The expression ratio of MT-CO1/ PPRC1
was also quantitated using qRT-PCR.
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Figure 51. 14-3-3σ suppresses pyruvate-to-lactate conversion in xenografted
breast tumors.
(A) Flag-14-3-3σ induction remarkably diminishes 13C pyruvate-to-13C lactate flux
in xenograft tumors. Pyruvate-to-lactate flux was measured by employing
hyperpolarized 13C-pyruvate tracer, following the time course at day 0 and day 14 (after
Flag-14-3-3σ induction) (left panels).
(B) Magnetic Resonance spectra show Flag-14-3-3σ induction decreased of 13C
lactate concentration in tumors.
(C) Flag-14-3-3σ expression decelerates the rate constant of 13C pyruvate-to- 13C
lactate reaction. kPL represents the rate constant of 13C pyruvate-to- 13C lactate
reaction. The ratio of kPL day 14 / kPL day 0 was calculated with (+) or without (-) induction of
Flag-14-3-3σ. All data is represented as mean ± 95% CI.
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Chapter 4. Discussions

Metabolic reprogramming has emerged as a new hallmark of cancers. Many
oncogenes or tumor suppressor genes are deregulated, which leads to abnormal
cellular bioenergetics that give cancer cells significant advantages either by providing
fuel for cancer cell growth and proliferation or creating microenvironments that facilitate
cancer invasion. Among alterations in cancer metabolism, increase in glycolysis and
glutaminolysis are two of the most prominent metabolic reprogramming events in tumor
(Dang, 2010a; Hanahan and Weinberg, 2011; Yeung et al., 2008). Furthermore,
mitochondrial biogenesis is also essential for cancer cells because mitochondria provide
not only energy but also important metabolites for rapid cell growth, proliferation and
biosynthesis (Wallace, 2012). Therefore, blocking these metabolic processes could
severely affect tumor cells.

Interestingly, our data indicate that 14-3-3σ could suppress all these three
essential metabolic pathways by promoting the degradation of their main driver, c-Myc.
Thus, our study reveals 14-3-3σ – Myc as a new axis of cancer metabolism regulation.
In addition, our findings also suggest that the tumor suppressor 14-3-3σ could be
considered as a potential target in anti-cancer metabolism therapy development.
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4.1 Lack of 14-3-3σ enhances glucose uptake in cancer cells
Enhanced glucose uptake and increased glycolysis are common and important
for most of cancer cells. Significantly, our clinical data analysis found an inverse
correlation between 14-3-3σ expression and PET SUVs of breast tumors (Figures 13A,
13B, Table 3). This could be because 14-3-3σ deficiency leads to upregulation of
glycolytic genes expression, especially glucose transporter genes, which are known
targets of Myc (Figures 15A, 15B, 16). Moreover, our experiments on human cancer cell
lines and mouse models confirm that 14-3-3σ can strongly inhibit the glucose uptake of
cancer cells both in vitro and in vivo (Figures 19-23; 48-51), providing a new insight into
our clinical observations.

The relationship between 14-3-3σ and PET SUVs could be further explained by
the fact that 14-3-3σ promotes Myc degradation via ubiquitination (Figures 30, 31),
thereby reducing the expression of important Myc-induced glucose transporters
(Figures 15, 35). In addition to the regulation at the transcriptional level, we also
observed that 14-3-3σ decreased Glut1 expression on cellular membrane surface
(Figure 23). Thus, it is conceivable that 14-3-3σ suppresses glucose uptake by downregulating the transcription and expression of important glucose transporters on cellular
membrane surface.

4.2 14-3-3σ increases Myc degradation and suppresses Myc transcriptional
activity
Myc is a major transcription factor that regulates multiple important cellular
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processes, including metabolism. Therefore, a complete understanding about Myc
stability regulation is essential. Our recent findings suggest that 14-3-3σ forms a homodimer to mediate the interaction between Myc and Pin1 (peptidylprolyl cis/trans

isomerase, NIMA-interacting 1) (Wen et al., 2012). Through this interaction, Pin1
induces a conformational change in the c-Myc protein, which facilitates Protein
Phosphatase 2A’s dephosphorylation of c-Myc at Serine 62 (Amati, 2004; Yeh et al.,
2004). Without a phosphate group at S62, c-Myc is degraded through an ubiquitinmediated pathway (Welcker et al., 2004; Yada et al., 2004) (Figure 52).

Similarly, in this study, we found a negative correlation between 14-3-3σ and Myc
protein levels in breast cancer patients’ tumors (Figure 18) and xenograft breast tumor
(Figure 49). In addition, 14-3-3σ induced Myc poly-ubiquitination, degradation and
accelerated Myc turnover rate in several cancer cell lines (Figures 30, 31). This 14-33σ-mediated down-regulation of Myc protein stability translated into effects that
negatively affect Myc target gene expression both in vitro and in vivo. Some of these
genes are involved in glycolysis (Figures 33-37, 49), glutaminolysis (Figures 40, 41, 49,
50A), and mitochondrial biogenesis (Figures 42, 43, 44, 50B). This important functional
link between Myc and 14-3-3σ provides an important insight into the relationship
between metabolic dysregulation and the frequent loss of 14-3-3σ during tumorigenesis.
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Figure 52. The mechanism of 14-3-3σ-enhanced Myc poly-ubiquitination and
degradation (adapted from Wen et al., 2012). 14-3-3σ forms a homo-dimer to mediate
the interaction between Myc and Pin1 (peptidylprolyl cis/trans isomerase, NIMA-

interacting 1) by binding to phosphorylated T343 on Myc and phosphorylated
S71 on Pin1 (Wen et al., 2012). Through this interaction, Pin1 induces a
conformational change in the c-Myc protein, which facilitates Protein Phosphatase 2A’s
dephosphorylation of c-Myc at Serine 62 (Amati, 2004; Yeh et al., 2004). Without a
phosphate group at S62, c-Myc with T58 phosphorylation is rapidly degraded through
an ubiquitin-mediated pathway (Welcker et al., 2004; Yada et al., 2004).
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4.3 14-3-3σ deficiency may facilitate tumor energy metabolism, cancer metastasis
and progression
14-3-3σ expression is frequently down-regulated during tumorigenesis process
(Ferguson et al., 2000; Lee and Lozano, 2006; Urano et al., 2002; Yang et al., 2006) as
well as in many aggressive metastatic breast cancer cell lines (Figure 11). In this study,
we showed that a high expression of 14-3-3σ in breast cancer patients’ tumors is
associated with increased breast cancer patients’ overall survival and metastasis-free
survival, while inversely correlated with tumor grade and glucose uptake of cancer cells
(Figures 12, 13, Tables 2 and 3). The positive impact of 14-3-3σ in improving cancer
patients’ clinical outcomes could be in part attributed to its ability in suppressing three
major Myc-induced cancer metabolic processes, i.e., glycolysis, glutaminolysis and
mitochondrial biogenesis. In fact, it has been well documented that these cancer
metabolic pathways are essential for tumor growth, proliferation, metastasis, survival
and drug resistance (Dang, 2010a; Hanahan and Weinberg, 2011; Wallace, 2012;
Yeung et al., 2008).

For instance, lactate, an important product of cancer aerobic glycolysis, has been
shown to induce cancer cell invasion and metastasis. Lactate can significantly enhance
cancer cell motility and facilitate the breaking down of extracellular matrix (Gatenby and
Gillies, 2004). Lactate also stimulates the migration of epithelial cancer cells and
promotes cancer metastasis to distant organs. For example, lactate administration
increases lung metastasis in a breast cancer mouse model (Bonuccelli et al., 2011). In
most of cancer cells, the increase in lactate production is primarily caused by the
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elevation of Lactate Dehydrogenase A (LDHA) and glycolytic genes, which are induced
by Myc and Hypoxia-Inducible Factor 1α (HIF1α) (Hanahan and Weinberg, 2011; Yeung
et al., 2008). Data from our study demonstrate the significant suppressive impact of 143-3σ on lactate production. Our measurements indicate that the loss or knockdown of
14-3-3σ leads to elevated lactate production while re-expression of 14-3-3σ reduces
lactate generation (Figures 24-28, 51). This elevation of lactate production upon 14-33σ deficiency is caused by the increase in glycolytic activity, glycolytic gene expression
(including LDHA) and PDHK1 upregulation (Figures 15, 16, 19-23, 30-37). Therefore
loss of 14-3-3σ enhances lactate production and may facilitate cancer cells metastasis.

In addition, the fact that 14-3-3σ null cells have a high concentration of ATP
means that cancer cells have an edge when it comes to cell growth and drug resistance
(Figure 29). This is because ATP is both a major DNA precursor often used for repairing
genetic damage and a key energy source for multidrug resistance efflux pumps that
discard toxic chemotherapy agents (Yeung et al., 2008). Furthermore, ATP and NAD+
from glycolysis can also be used by poly(ADP-ribose) polymerase (PARP-1) and ADPribosyl transferase to repair DNA damage caused by radiation and chemotherapy.
Glycolysis also fuels pentose phosphate pathway (PPP) by providing glucose-6phosphate. PPP generates nucleotides that are important for DNA damage repair.
Moreover, PPP also supplies cancer cells with NADPH, a potent reductant that can be
utilized by cytochrome P450 to detoxify toxic chemotherapy agents (Yeung et al., 2008).
Thus, by blocking glycolysis, 14-3-3σ also contributes to reducing the resistance of
tumors to anti-cancer therapies.
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It has also been reported that glycolytic enzymes play important roles in cancer
cell survival. For example, Hexokinase 2 (HK2) blocks cytochrome c release from
mitochondria (Majewski et al., 2004; Pastorino et al., 2002), thereby protecting cancer
cells from apoptosis. Indeed, our results show that 14-3-3σ expression reduces HK2
level while increasing caspase 3 cleavage in xenograft tumors (Figure 49). Additionally,
Glucose-6-phosphate isomerase (GPI) has been shown to stimulate cell motility, an
important step in the metastatic process (Funasaka et al., 2007) (Funasaka and Raz,
2007). In fact, our data showed that 14-3-3σ expression reduced GPI level (Figure 35).
Therefore, the fact that loss of 14-3-3σ expression elevates the levels of these glycolytic
enzymes has a broad impact not only on tumor bioenergetics but also other hallmarks
of cancers.

4.4 14-3-3σ suppresses cancer glutaminolysis, mitochondria biogenesis and may
affect amino acids, phospholipids and nucleotides biosynthesis
Glutaminolysis is both a major source of precursors for large-scale biosynthesis
and a vital energy source for cancer cells (Dang, 2010a). In this process, glutamine is
transported by glutamine transporters and is converted to α-ketoglutarate (α-KG) to
replenish biosynthetic intermediates of the TCA cycle. It is important to point out that 143-3σ re-expression in 14-3-3σ null cells leads to the reduction of glutamate
concentration levels, indicating that 14-3-3σ may suppress glutaminolysis (Figure 24C).
Indeed, our biochemical data shows that re-expression of 14-3-3σ in 14-3-3σ null cells
can down-regulate the Myc-activated genes involved in glutaminolysis (Figures 15, 40,
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41, 49A, 50A). Given the important role of glutaminolysis in cancer metabolism, by
suppressing this major metabolic pathway, 14-3-3σ may also negatively affect other
metabolic processes in tumor cells.

Similarly, mitochondria are crucial for cancer cells because mitochondria are not
only the cellular power stations but also factories that produce many important
precursors for amino acid (oxaloacetate, α-ketoglutarate), lipid (citrate), heme group
(succinyl CoA), and nucleotide (oxaloacetate transaminated to aspartate) biosyntheses.
As a result, a strong decline in mitochondrial mass could have a deleterious impact on
cancer cell growth (Wallace, 2012). Therefore, the fact that 14-3-3σ expression
markedly reduced Myc-induced mitochondrial biogenesis, TFAM level and the
expression of mitochondrial genes (Figures 42-44, 50B) suggests a widespread
negative impact of 14-3-3σ on cancer metabolism. Indeed, our Nuclear Magnetic
Resonance analysis demonstrated that 14-3-3σ expression correlates with a strong
diminishment of many key amino acids (e.g., methionine, glutamate, glutamine, and
arginine), phospholipid metabolites and precursors for nucleotide synthesis (Figure
24C). However, it is still unclear whether the reduction in amino acid and phospholipid
levels is a direct effect of 14-3-3σ, a consequence of 14-3-3σ-mediated suppression of
glycolysis, glutaminolysis and mitochondrial biogenesis, or both.

On the other hand, since Myc can induce multiple metabolic pathways, Myc
helps cancer cells effectively adapt to microenvironments with fluctuating oxygen levels
(both normoxia and hypoxia), and consume different sources of nutrients (e.g., glucose,
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glutamine, among others) to fuel their metabolism and support their rapid proliferation.
Therefore, by promoting Myc degradation, 14-3-3σ may severely affect the adaptability
of cancer cells and the versatility of their metabolism.

4.5 Conclusions
In conclusion, this study identifies a new function of 14-3-3σ in controlling cancer
metabolism, especially glycolysis, glutaminolysis and mitochondrial biogenesis. 14-3-3σ
also has a negative and broad impact on cancer bioenergetics. In addition, 14-3-3σ
exerts its suppressive influence on major cancer metabolic pathways by promoting cMyc polyubiquitination and degradation.
Moreover, since 14-3-3σ is a direct p53 target gene, our findings may provide an
additional insight into the regulation of cancer metabolism by p53. Furthermore, given
the significantly positive impact of 14-3-3σ on patients’ clinical outcomes and 14-3-3σ
remarkable suppressive influence on cancer bioenergetics, we think that restoration of
14-3-3σ expression in cancer cells could be considered as a potential anti-cancer
metabolism therapy.

4.6 Future research directions
Despite the new findings about the impact of 14-3-3σ on cancer metabolism from
this study, there are still a couple of unanswered questions that could be considered as
potential research directions in future. First of all, it is also important to determine
whether 14-3-3σ can directly regulate the function, localization and stability of glycolytic
enzymes. Our preliminary data suggest that 14-3-3σ may associate with Hexokinase 2
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and suppress the function of this kinase, which implies a direct effect of 14-3-3σ on
cancer glycolysis. Secondly, whether 14-3-3σ can regulate HIF1α is an interesting
research direction. Our results show that 14-3-3σ can significantly inhibit glycolysis in
hypoxia and down-regulates the expression of glycolytic enzymes (Figures 34 and 35).
Since HIF1α is crucial for cancer cell survival and HIF1α is the major driver of glycolysis
under hypoxic condition, it is intriguing to determine whether 14-3-3σ may block the
activity or down-regulate this transcription factor. In addition, as 14-3-3σ can suppress
tumorigenesis in multiple ways, for instance by suppressing cancer energy metabolism,
decreasing cell proliferation, promoting c-Myc degradation, and stabilizing p53,
restoration of 14-3-3σ expression in cancer cells using gene therapy or nanoparticles is
a promising anti-cancer therapy.
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Figure 53. 14-3-3σ has a broad negative impact on cancer metabolic network.
Glycolysis and glutaminolysis provide important precursors and energy to support the
rapid proliferation and large-scale biosynthesis in cancer cells. For instance, glucose-6phosphate from glycolysis can be used in pentose phosphate pathway to synthesize
nucleotides and NADPH. Dihydroxyacetone phosphate may be mobilized to produce
lipids. Furthermore, the intermediates of TCA cycle that originate from glutaminolysis
are important to generate amino acids, lipids, nucleotides, sterols, among other crucial
macromolecules. The energy and metabolites derived from glycolysis and
glutaminolysis are crucial for tumor growth, survival, proliferation, metastasis and
resistance to anti-cancer therapies. On the other hand, mitochondrial biogenesis is also
essential for tumorigenesis because mitochondria are the nexus of many energy
production and metabolic pathways. Hence, mitochondria are vital for tumor cells to
meet their constant demands for energy and materials to support their fast growth and
division. Myc is a main driver of all these crucial cellular processes as well as other
major metabolic pathways, enabling tumor cells to consume different nutrient sources
for their survival and proliferation as well as to effectively adapt to various conditions.
Therefore, the negative impact of 14-3-3σ on Myc stability results in a broad inhibitory
effect on cancer bioenergetics and the versatility of their metabolism. Consequently, 143-3σ expression decreases metabolic activities in cancer cells and may ultimately
suppress tumor growth, division, metastasis, survival and resistance to therapies. Thus,
this study identifies a new function of 14-3-3σ in controlling cancer glycolysis,
glutaminolysis and mitochondrial biogenesis by promoting Myc degradation, suggesting
14-3-3σ-Myc as a new regulatory axis of cancer metabolism. Moreover, since 14-3-3σ is
a direct p53 target gene, these findings may provide an additional insight into the
regulation of cancer metabolism by p53. Furthermore, based on the vital role of cancer
metabolism in tumorigenesis and the remarkable inhibitory influence of 14-3-3σ on
major cancer metabolic pathways, we think that restoration of 14-3-3σ expression in
cancer cells could be considered as a anti-cancer metabolism therapy.
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